"use strict";(self.webpackChunkbuild_back_better_breakdown=self.webpackChunkbuild_back_better_breakdown||[]).push([[169],{3905:function(e,n,t){t.d(n,{Zo:function(){return h},kt:function(){return l}});var a=t(7294);function r(e,n,t){return n in e?Object.defineProperty(e,n,{value:t,enumerable:!0,configurable:!0,writable:!0}):e[n]=t,e}function i(e,n){var t=Object.keys(e);if(Object.getOwnPropertySymbols){var a=Object.getOwnPropertySymbols(e);n&&(a=a.filter((function(n){return Object.getOwnPropertyDescriptor(e,n).enumerable}))),t.push.apply(t,a)}return t}function o(e){for(var n=1;n<arguments.length;n++){var t=null!=arguments[n]?arguments[n]:{};n%2?i(Object(t),!0).forEach((function(n){r(e,n,t[n])})):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(t)):i(Object(t)).forEach((function(n){Object.defineProperty(e,n,Object.getOwnPropertyDescriptor(t,n))}))}return e}function s(e,n){if(null==e)return{};var t,a,r=function(e,n){if(null==e)return{};var t,a,r={},i=Object.keys(e);for(a=0;a<i.length;a++)t=i[a],n.indexOf(t)>=0||(r[t]=e[t]);return r}(e,n);if(Object.getOwnPropertySymbols){var i=Object.getOwnPropertySymbols(e);for(a=0;a<i.length;a++)t=i[a],n.indexOf(t)>=0||Object.prototype.propertyIsEnumerable.call(e,t)&&(r[t]=e[t])}return r}var c=a.createContext({}),d=function(e){var n=a.useContext(c),t=n;return e&&(t="function"==typeof e?e(n):o(o({},n),e)),t},h=function(e){var n=d(e.components);return a.createElement(c.Provider,{value:n},e.children)},u={inlineCode:"code",wrapper:function(e){var n=e.children;return a.createElement(a.Fragment,{},n)}},p=a.forwardRef((function(e,n){var t=e.components,r=e.mdxType,i=e.originalType,c=e.parentName,h=s(e,["components","mdxType","originalType","parentName"]),p=d(t),l=r,f=p["".concat(c,".").concat(l)]||p[l]||u[l]||i;return t?a.createElement(f,o(o({ref:n},h),{},{components:t})):a.createElement(f,o({ref:n},h))}));function l(e,n){var t=arguments,r=n&&n.mdxType;if("string"==typeof e||r){var i=t.length,o=new Array(i);o[0]=p;var s={};for(var c in n)hasOwnProperty.call(n,c)&&(s[c]=n[c]);s.originalType=e,s.mdxType="string"==typeof e?e:r,o[1]=s;for(var d=2;d<i;d++)o[d]=t[d];return a.createElement.apply(null,o)}return a.createElement.apply(null,t)}p.displayName="MDXCreateElement"},2395:function(e,n,t){t.r(n),t.d(n,{frontMatter:function(){return s},contentTitle:function(){return c},metadata:function(){return d},toc:function(){return h},default:function(){return p}});var a=t(7462),r=t(3366),i=(t(7294),t(3905)),o=["components"],s={sidebar_position:25},c=void 0,d={unversionedId:"title-13-committee-on-ways-and-means/title-13-remaining-text",id:"title-13-committee-on-ways-and-means/title-13-remaining-text",title:"title-13-remaining-text",description:"\x3c!--",source:"@site/docs/title-13-committee-on-ways-and-means/title-13-remaining-text.md",sourceDirName:"title-13-committee-on-ways-and-means",slug:"/title-13-committee-on-ways-and-means/title-13-remaining-text",permalink:"/build-back-better-breakdown/docs/title-13-committee-on-ways-and-means/title-13-remaining-text",editUrl:"https://github.com/EdwardAngert/build-back-better-breakdown/tree/main/packages/create-docusaurus/templates/shared/docs/title-13-committee-on-ways-and-means/title-13-remaining-text.md",tags:[],version:"current",sidebarPosition:25,frontMatter:{sidebar_position:25},sidebar:"tutorialSidebar",previous:{title:"Part 5 - Other Provisions",permalink:"/build-back-better-breakdown/docs/title-13-committee-on-ways-and-means/title-13-subtitle-i/title-13-subtitle-i-part-5"}},h=[],u={toc:h};function p(e){var n=e.components,t=(0,r.Z)(e,o);return(0,i.kt)("wrapper",(0,a.Z)({},u,t,{components:n,mdxType:"MDXLayout"}),(0,i.kt)("hr",null),(0,i.kt)("pre",null,(0,i.kt)("code",{parentName:"pre"},"                    Subtitle J--Drug Pricing\n\n  PART 1--LOWERING PRICES THROUGH FAIR DRUG PRICE NEGOTIATION\n")),(0,i.kt)("p",null,"SEC. 139001. PROVIDING FOR LOWER PRICES FOR CERTAIN HIGH-PRICED SINGLE\nSOURCE DRUGS."),(0,i.kt)("pre",null,(0,i.kt)("code",{parentName:"pre"},"(a) Program To Lower Prices for Certain High-Priced Single Source \n")),(0,i.kt)("p",null,"Drugs.--Title XI of the Social Security Act (42 U.S.C. 1301 et seq.) is\namended by adding at the end the following new part:"),(0,i.kt)("p",null," ``PART E--FAIR PRICE NEGOTIATION PROGRAM TO LOWER PRICES FOR CERTAIN\nHIGH-PRICED SINGLE SOURCE DRUGS"),(0,i.kt)("p",null,"``SEC. 1191. ESTABLISHMENT OF PROGRAM."),(0,i.kt)("pre",null,(0,i.kt)("code",{parentName:"pre"},"``(a) In General.--The Secretary shall establish a Fair Price \n")),(0,i.kt)("p",null,"Negotiation Program (in this part referred to as the ",(0,i.kt)("inlineCode",{parentName:"p"},"program'). Under \nthe program, with respect to each price applicability period, the \nSecretary shall--\n            ``(1) publish a list of selected drugs in accordance with \n        section 1192;\n            ``(2) enter into agreements with manufacturers of selected \n        drugs with respect to such period, in accordance with section \n        1193;\n            ``(3) negotiate and, if applicable, renegotiate maximum \n        fair prices for such selected drugs, in accordance with section \n        1194; and\n            ``(4) carry out the administrative duties described in \n        section 1196.\n    ``(b) Definitions Relating to Timing.--For purposes of this part:\n            ``(1) Initial price applicability year.--The term "),"initial\nprice applicability year' means a plan year (beginning with\nplan year 2025) or, if agreed to in an agreement under section\n1193 by the Secretary and manufacturer involved, a period of\nmore than one plan year (beginning on or after January 1,\n2025).\n",(0,i.kt)("inlineCode",{parentName:"p"},"(2) Price applicability period.--The term `price \n        applicability period' means, with respect to a drug, the period \n        beginning with the initial price applicability year with \n        respect to which such drug is a selected drug and ending with \n        the last plan year during which the drug is a selected drug.\n            "),"(3) Selected drug publication date.--The term ",(0,i.kt)("inlineCode",{parentName:"p"},"selected \n        drug publication date' means, with respect to each initial \n        price applicability year, April 15 of the plan year that begins \n        2 years prior to such year.\n            ``(4) Voluntary negotiation period.--The term "),"voluntary\nnegotiation period' means, with respect to an initial price\napplicability year with respect to a selected drug, the\nperiod--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(A) beginning on the sooner of--\n                            "),"(i) the date on which the manufacturer of\nthe drug and the Secretary enter into an\nagreement under section 1193 with respect to\nsuch drug; or\n",(0,i.kt)("inlineCode",{parentName:"p"},"(ii) June 15 following the selected drug \n                        publication date with respect to such selected \n                        drug; and\n                    "),"(B) ending on March 31 of the year that begins\none year prior to the initial price applicability year.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(c) Other Definitions.--For purposes of this part:\n            "),"(1) Fair price eligible individual.--The term ",(0,i.kt)("inlineCode",{parentName:"p"},"fair price \n        eligible individual' means, with respect to a selected drug--\n                    ``(A) in the case such drug is furnished or \n                dispensed to the individual at a pharmacy or by a mail \n                order service--\n                            ``(i) an individual who is enrolled under a \n                        prescription drug plan under part D of title \n                        XVIII or an MA-PD plan under part C of such \n                        title if coverage is provided under such plan \n                        for such selected drug; and\n                            ``(ii) an individual who is enrolled under \n                        a group health plan or health insurance \n                        coverage offered in the group or individual \n                        market (as such terms are defined in section \n                        2791 of the Public Health Service Act) with \n                        respect to which there is in effect an \n                        agreement with the Secretary under section 1197 \n                        with respect to such selected drug as so \n                        furnished or dispensed; and\n                    ``(B) in the case such drug is furnished or \n                administered to the individual by a hospital, \n                physician, or other provider of services or supplier--\n                            ``(i) an individual who is entitled to \n                        benefits under part A of title XVIII or \n                        enrolled under part B of such title if such \n                        selected drug is covered under the respective \n                        part; and\n                            ``(ii) an individual who is enrolled under \n                        a group health plan or health insurance \n                        coverage offered in the group or individual \n                        market (as such terms are defined in section \n                        2791 of the Public Health Service Act) with \n                        respect to which there is in effect an \n                        agreement with the Secretary under section 1197 \n                        with respect to such selected drug as so \n                        furnished or administered.\n            ``(2) Maximum fair price.--The term "),"maximum fair price'\nmeans, with respect to a plan year during a price applicability\nperiod and with respect to a selected drug (as defined in\nsection 1192(c)) with respect to such period, the price\npublished pursuant to section 1195 in the Federal Register for\nsuch drug and year.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(3) Average international market price defined.--\n                    "),"(A) In general.--The terms ",(0,i.kt)("inlineCode",{parentName:"p"},"average international \n                market price' and "),"AIM price' mean, with respect to a\ndrug, the average price (which shall be the net average\nprice, if practicable, and volume-weighted, if\npracticable) for a unit (as defined in paragraph (4))\nof the drug for sales of such drug (calculated across\ndifferent dosage forms and strengths of the drug and\nnot based on the specific formulation or package size\nor package type), as computed (as of the date of\npublication of such drug as a selected drug under\nsection 1192(a)) in all countries described in clause\n(ii) of subparagraph (B) that are applicable countries\n(as described in clause (i) of such subparagraph) with\nrespect to such drug.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(B) Applicable countries.--\n                            "),"(i) In general.--For purposes of\nsubparagraph (A), a country described in clause\n(ii) is an applicable country described in this\nclause with respect to a drug if there is\navailable an average price for any unit for the\ndrug for sales of such drug in such country.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(ii) Countries described.--For purposes \n                        of this paragraph, the following are countries \n                        described in this clause:\n                                    "),"(I) Australia.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(II) Canada.\n                                    "),"(III) France.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(IV) Germany.\n                                    "),"(V) Japan.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(VI) The United Kingdom.\n            "),"(4) Unit.--The term `unit' means, with respect to a drug,\nthe lowest identifiable quantity (such as a capsule or tablet,\nmilligram of molecules, or grams) of the drug that is\ndispensed."),(0,i.kt)("p",null,"``SEC. 1192. SELECTION OF NEGOTIATION-ELIGIBLE DRUGS AS SELECTED DRUGS."),(0,i.kt)("pre",null,(0,i.kt)("code",{parentName:"pre"},"``(a) In General.--Not later than the selected drug publication \n")),(0,i.kt)("p",null,"date with respect to an initial price applicability year, subject to\nsubsection (h), the Secretary shall select and publish in the Federal\nRegister a list of--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(1)(A) with respect to an initial price applicability \n        year during 2025, at least 25 negotiation-eligible drugs \n        described in subparagraphs (A) and (B), but not subparagraph \n        (C), of subsection (d)(1) (or, with respect to an initial price \n        applicability year during such period beginning after 2025, the \n        maximum number (if such number is less than 25) of such \n        negotiation-eligible drugs for the year) with respect to such \n        year; and\n            "),"(B) with respect to an initial price applicability year\nduring 2026 or a subsequent year, at least 50 negotiation-\neligible drugs described in subparagraphs (A) and (B), but not\nsubparagraph (C), of subsection (d)(1) (or, with respect to an\ninitial price applicability year during such period, the\nmaximum number (if such number is less than 50) of such\nnegotiation-eligible drugs for the year) with respect to such\nyear;\n",(0,i.kt)("inlineCode",{parentName:"p"},"(2) all negotiation-eligible drugs described in \n        subparagraph (C) of such subsection with respect to such year; \n        and\n            "),"(3) all new-entrant negotiation-eligible drugs (as\ndefined in subsection (g)(1)) with respect to such year.\nEach drug published on the list pursuant to the previous sentence shall\nbe subject to the negotiation process under section 1194 for the\nvoluntary negotiation period with respect to such initial price\napplicability year (and the renegotiation process under such section as\napplicable for any subsequent year during the applicable price\napplicability period). In applying this subsection, any negotiation-\neligible drug that is selected under this subsection for an initial\nprice applicability year shall not count toward the required minimum\namount of drugs to be selected under paragraph (1) for any subsequent\nyear, including such a drug so selected that is subject to\nrenegotiation under section 1194.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(b) Selection of Drugs.--In carrying out subsection (a)(1) the \nSecretary shall select for inclusion on the published list described in \nsubsection (a) with respect to a price applicability period, the \nnegotiation-eligible drugs that the Secretary projects will result in \nthe greatest savings to the Federal Government or fair price eligible \nindividuals during the price applicability period. In making this \nprojection of savings for drugs for which there is an AIM price for a \nprice applicability period, the savings shall be projected across \ndifferent dosage forms and strengths of the drugs and not based on the \nspecific formulation or package size or package type of the drugs, \ntaking into consideration both the volume of drugs for which payment is \nmade, to the extent such data is available, and the amount by which the \nnet price for the drugs exceeds the AIM price for the drugs.\n    "),"(c) Selected Drug.--For purposes of this part, each drug included\non the list published under subsection (a) with respect to an initial\nprice applicability year shall be referred to as a ",(0,i.kt)("inlineCode",{parentName:"p"},"selected drug' with \nrespect to such year and each subsequent plan year beginning before the \nfirst plan year beginning after the date on which the Secretary \ndetermines two or more drug products--\n            ``(1) are approved or licensed (as applicable)--\n                    ``(A) under section 505(j) of the Federal Food, \n                Drug, and Cosmetic Act using such drug as the listed \n                drug; or\n                    ``(B) under section 351(k) of the Public Health \n                Service Act using such drug as the reference product; \n                and\n            ``(2) continue to be marketed.\n    ``(d) Negotiation-Eligible Drug.--\n            ``(1) In general.--For purposes of this part, the term \n        "),"negotiation-eligible drug' means, with respect to the selected\ndrug publication date with respect to an initial price\napplicability year, a qualifying single source drug, as defined\nin subsection (e), that meets any of the following criteria:\n",(0,i.kt)("inlineCode",{parentName:"p"},"(A) Covered part d drugs.--The drug is among the \n                125 covered part D drugs (as defined in section 1860D-\n                2(e)) for which there was an estimated greatest net \n                spending under parts C and D of title XVIII, as \n                determined by the Secretary, during the most recent \n                plan year prior to such drug publication date for which \n                data are available.\n                    "),"(B) Other drugs.--The drug is among the 125 drugs\nfor which there was an estimated greatest net spending\nin the United States (including the 50 States, the\nDistrict of Columbia, and the territories of the United\nStates), as determined by the Secretary, during the\nmost recent plan year prior to such drug publication\ndate for which data are available.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(C) Insulin.--The drug is a qualifying single \n                source drug described in subsection (e)(3).\n            "),"(2) Clarification.--In determining whether a qualifying\nsingle source drug satisfies any of the criteria described in\nparagraph (1), the Secretary shall, to the extent practicable,\nuse data that is aggregated across dosage forms and strengths\nof the drug and not based on the specific formulation or\npackage size or package type of the drug.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(3) Publication.--Not later than the selected drug \n        publication date with respect to an initial price applicability \n        year, the Secretary shall publish in the Federal Register a \n        list of negotiation-eligible drugs with respect to such \n        selected drug publication date.\n    "),"(e) Qualifying Single Source Drug.--For purposes of this part,\nthe term ",(0,i.kt)("inlineCode",{parentName:"p"},"qualifying single source drug' means any of the following:\n            ``(1) Drug products.--A drug that--\n                    ``(A) is approved under section 505(c) of the \n                Federal Food, Drug, and Cosmetic Act and continues to \n                be marketed pursuant to such approval; and\n                    ``(B) is not the listed drug for any drug that is \n                approved and continues to be marketed under section \n                505(j) of such Act.\n            ``(2) Biological products.--A biological product that--\n                    ``(A) is licensed under section 351(a) of the \n                Public Health Service Act, including any product that \n                has been deemed to be licensed under section 351 of \n                such Act pursuant to section 7002(e)(4) of the \n                Biologics Price Competition and Innovation Act of 2009, \n                and continues to be marketed under section 351 of such \n                Act; and\n                    ``(B) is not the reference product for any \n                biological product that is licensed and continues to be \n                marketed under section 351(k) of such Act.\n            ``(3) Insulin product.--Notwithstanding paragraphs (1) and \n        (2), any insulin product that is approved under subsection (c) \n        or (j) of section 505 of the Federal Food, Drug, and Cosmetic \n        Act or licensed under subsection (a) or (k) of section 351 of \n        the Public Health Service Act and continues to be marketed \n        under such section 505 or 351, including any insulin product \n        that has been deemed to be licensed under section 351(a) of the \n        Public Health Service Act pursuant to section 7002(e)(4) of the \n        Biologics Price Competition and Innovation Act of 2009 and \n        continues to be marketed pursuant to such licensure.\nFor purposes of applying paragraphs (1) and (2), a drug or biological \nproduct that is marketed by the same sponsor or manufacturer (or an \naffiliate thereof or a cross-licensed producer or distributor) as the \nlisted drug or reference product described in such respective paragraph \nshall not be taken into consideration.\n    ``(f) Information on International Drug Prices.--For purposes of \ndetermining which negotiation-eligible drugs to select under subsection \n(a) and, in the case of such drugs that are selected drugs, to \ndetermine the maximum fair price for such a drug and whether such \nmaximum fair price should be renegotiated under section 1194, the \nSecretary shall use data relating to the AIM price with respect to such \ndrug as available or provided to the Secretary and shall on an ongoing \nbasis request from manufacturers of selected drugs information on the \nAIM price of such a drug.\n    ``(g) New-Entrant Negotiation-Eligible Drugs.--\n            ``(1) In general.--For purposes of this part, the term \n        "),"new-entrant negotiation-eligible drug' means, with respect to\nthe selected drug publication date with respect to an initial\nprice applicability year, a qualifying single source drug--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(A) that is first approved or licensed, as \n                described in paragraph (1), (2), or (3) of subsection \n                (e), as applicable, during the year preceding such \n                selected drug publication date; and\n                    "),"(B) that the Secretary determines under paragraph\n(2) is likely to be included as a negotiation-eligible\ndrug with respect to the subsequent selected drug\npublication date.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(2) Determination.--In the case of a qualifying single \n        source drug that meets the criteria described in subparagraph \n        (A) of paragraph (1), with respect to an initial price \n        applicability year, if the wholesale acquisition cost at which \n        such drug is first marketed in the United States is equal to or \n        greater than the median household income (as determined \n        according to the most recent data collected by the United \n        States Census Bureau), the Secretary shall determine before the \n        selected drug publication date with respect to the initial \n        price applicability year, if the drug is likely to be included \n        as a negotiation-eligible drug with respect to the subsequent \n        selected drug publication date, based on the projected spending \n        under title XVIII or in the United States on such drug. For \n        purposes of this paragraph the term `United States' includes \n        the 50 States, the District of Columbia, and the territories of \n        the United States.\n    "),"(h) Conflict of Interest.--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(1) In general.--In the case the Inspector General of the \n        Department of Health and Human Services determines the \n        Secretary has a conflict, with respect to a matter described in \n        paragraph (2), the individual described in paragraph (3) shall \n        carry out the duties of the Secretary under this part, with \n        respect to a negotiation-eligible drug, that would otherwise be \n        such a conflict.\n            "),"(2) Matter described.--A matter described in this\nparagraph is--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(A) a financial interest (as described in section \n                2635.402 of title 5, Code of Federal Regulations, as in \n                effect on the date of the enactment of this section, \n                (except for an interest described in subsection \n                (b)(2)(iv) of such section)) on the date of the \n                selected drug publication date, with respect the price \n                applicability year (as applicable);\n                    "),"(B) a personal or business relationship (as\ndescribed in section 2635.502 of such title) on the\ndate of the selected drug publication date, with\nrespect the price applicability year;\n",(0,i.kt)("inlineCode",{parentName:"p"},"(C) employment by a manufacturer of a \n                negotiation-eligible drug during the preceding 10-year \n                period beginning on the date of the selected drug \n                publication date, with respect to each price \n                applicability year; and\n                    "),"(D) any other matter the General Counsel\ndetermines appropriate.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(3) Individual described.--An individual described in \n        this paragraph is--\n                    "),"(A) the highest-ranking officer or employee of\nthe Department of Health and Human Services (as\ndetermined by the organizational chart of the\nDepartment) that does not have a conflict under this\nsubsection; and\n``(B) is nominated by the President and confirmed\nby the Senate with respect to the position."),(0,i.kt)("p",null,"``SEC. 1193. MANUFACTURER AGREEMENTS."),(0,i.kt)("pre",null,(0,i.kt)("code",{parentName:"pre"},"``(a) In General.--For purposes of section 1191(a)(2), the \n")),(0,i.kt)("p",null,"Secretary shall enter into agreements with manufacturers of selected\ndrugs with respect to a price applicability period, by not later than\nJune 15 following the selected drug publication date with respect to\nsuch selected drug, under which--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(1) during the voluntary negotiation period for the \n        initial price applicability year for the selected drug, the \n        Secretary and manufacturer, in accordance with section 1194, \n        negotiate to determine (and, by not later than the last date of \n        such period and in accordance with subsection (c), agree to) a \n        maximum fair price for such selected drug of the manufacturer \n        in order to provide access to such price--\n                    "),"(A) to fair price eligible individuals who with\nrespect to such drug are described in subparagraph (A)\nof section 1191(c)(1) and are furnished or dispensed\nsuch drug during, subject to subparagraph (2), the\nprice applicability period; and\n",(0,i.kt)("inlineCode",{parentName:"p"},"(B) to hospitals, physicians, and other providers \n                of services and suppliers with respect to fair price \n                eligible individuals who with respect to such drug are \n                described in subparagraph (B) of such section and are \n                furnished or administered such drug during, subject to \n                subparagraph (2), the price applicability period;\n            "),"(2) the Secretary and the manufacturer shall, in\naccordance with a process and during a period specified by the\nSecretary pursuant to rulemaking, renegotiate (and, by not\nlater than the last date of such period and in accordance with\nsubsection (c), agree to) the maximum fair price for such drug\nif the Secretary determines that there is a material change in\nany of the factors described in section 1194(d) relating to the\ndrug, including changes in the AIM price for such drug, in\norder to provide access to such maximum fair price (as so\nrenegotiated)--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(A) to fair price eligible individuals who with \n                respect to such drug are described in subparagraph (A) \n                of section 1191(c)(1) and are furnished or dispensed \n                such drug during any year during the price \n                applicability period (beginning after such \n                renegotiation) with respect to such selected drug; and\n                    "),"(B) to hospitals, physicians, and other providers\nof services and suppliers with respect to fair price\neligible individuals who with respect to such drug are\ndescribed in subparagraph (B) of such section and are\nfurnished or administered such drug during any year\ndescribed in subparagraph (A);\n",(0,i.kt)("inlineCode",{parentName:"p"},"(3) the maximum fair price (including as renegotiated \n        pursuant to paragraph (2)), with respect to such a selected \n        drug, shall be provided to fair price eligible individuals, who \n        with respect to such drug are described in subparagraph (A) of \n        section 1191(c)(1), at the pharmacy or by a mail order service \n        at the point-of-sale of such drug;\n            "),"(4) the manufacturer, subject to subsection (d), submits\nto the Secretary, in a form and manner specified by the\nSecretary--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(A) for the voluntary negotiation period for the \n                price applicability period (and, if applicable, before \n                any period of renegotiation specified pursuant to \n                paragraph (2)) with respect to such drug all \n                information that the Secretary requires to carry out \n                the negotiation (or renegotiation process) under this \n                part, including information described in section \n                1192(f) and section 1194(d)(1); and\n                    "),"(B) on an ongoing basis, information on changes\nin prices for such drug that would affect the AIM price\nfor such drug or otherwise provide a basis for\nrenegotiation of the maximum fair price for such drug\npursuant to paragraph (2);\n",(0,i.kt)("inlineCode",{parentName:"p"},"(5) the manufacturer agrees that in the case the selected \n        drug of a manufacturer is a drug described in subsection (c), \n        the manufacturer will, in accordance with such subsection, make \n        any payment required under such subsection with respect to such \n        drug; and\n            "),"(6) the manufacturer complies with requirements imposed\nby the Secretary for purposes of administering the program,\nincluding with respect to the duties described in section 1196.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(b) Agreement in Effect Until Drug Is No Longer a Selected \nDrug.--An agreement entered into under this section shall be effective, \nwith respect to a drug, until such drug is no longer considered a \nselected drug under section 1192(c).\n    "),"(c) Special Rule for Certain Selected Drugs Without AIM Price.--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(1) In general.--In the case of a selected drug for which \n        there is no AIM price available with respect to the initial \n        price applicability year for such drug and for which an AIM \n        price becomes available beginning with respect to a subsequent \n        plan year during the price applicability period for such drug, \n        if the Secretary determines that the amount described in \n        paragraph (2)(A) for a unit of such drug is greater than the \n        amount described in paragraph (2)(B) for a unit of such drug, \n        then by not later than one year after the date of such \n        determination, the manufacturer of such selected drug shall pay \n        to the Treasury an amount equal to the product of--\n                    "),"(A) the difference between such amount described\nin paragraph (2)(A) for a unit of such drug and such\namount described in paragraph (2)(B) for a unit of such\ndrug; and\n",(0,i.kt)("inlineCode",{parentName:"p"},"(B) the number of units of such drug sold in the \n                United States, including the 50 States, the District of \n                Columbia, and the territories of the United States, \n                during the period described in paragraph (2)(B).\n            "),"(2) Amounts described.--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(A) Weighted average price before aim price \n                available.--For purposes of paragraph (1), the amount \n                described in this subparagraph for a selected drug \n                described in such paragraph, is the amount equal to the \n                weighted average manufacturer price (as defined in \n                section 1927(k)(1)) for such dosage strength and form \n                for the drug during the period beginning with the first \n                plan year for which the drug is included on the list of \n                negotiation-eligible drugs published under section \n                1192(d) and ending with the last plan year during the \n                price applicability period for such drug with respect \n                to which there is no AIM price available for such drug.\n                    "),"(B) Amount multiplier after aim price\navailable.--For purposes of paragraph (1), the amount\ndescribed in this subparagraph for a selected drug\ndescribed in such paragraph, is the amount equal to 200\npercent of the AIM price for such drug with respect to\nthe first plan year during the price applicability\nperiod for such drug with respect to which there is an\nAIM price available for such drug.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(d) Confidentiality of Information.--Information submitted to the \nSecretary under this part by a manufacturer of a selected drug that is \nproprietary information of such manufacturer (as determined by the \nSecretary) may be used only by the Secretary or disclosed to and used \nby the Comptroller General of the United States or the Medicare Payment \nAdvisory Commission for purposes of carrying out this part.\n    "),"(e) Regulations.--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(1) In general.--The Secretary shall, pursuant to \n        rulemaking, specify, in accordance with paragraph (2), the \n        information that must be submitted under subsection (a)(4).\n            "),"(2) Information specified.--Information described in\nparagraph (1), with respect to a selected drug, shall include\ninformation on sales of the drug (by the manufacturer of the\ndrug or by another entity under license or other agreement with\nthe manufacturer, with respect to the sales of such drug,\nregardless of the name under which the drug is sold) in any\nforeign country that is part of the AIM price. The Secretary\nshall verify, to the extent practicable, such sales from\nappropriate officials of the government of the foreign country\ninvolved.\n``(f) Compliance With Requirements for Administration of Program.--\nEach manufacturer with an agreement in effect under this section shall\ncomply with requirements imposed by the Secretary or a third party with\na contract under section 1196(c)(1), as applicable, for purposes of\nadministering the program."),(0,i.kt)("p",null,"``SEC. 1194. NEGOTIATION AND RENEGOTIATION PROCESS."),(0,i.kt)("pre",null,(0,i.kt)("code",{parentName:"pre"},"``(a) In General.--For purposes of this part, under an agreement \n")),(0,i.kt)("p",null,"under section 1193 between the Secretary and a manufacturer of a\nselected drug, with respect to the period for which such agreement is\nin effect and in accordance with subsections (b) and (c), the Secretary\nand the manufacturer--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(1) shall during the voluntary negotiation period with \n        respect to the initial price applicability year for such drug, \n        in accordance with this section, negotiate a maximum fair price \n        for such drug for the purpose described in section 1193(a)(1); \n        and\n            "),"(2) as applicable pursuant to section 1193(a)(2) and in\naccordance with the process specified pursuant to such section,\nrenegotiate such maximum fair price for such drug for the\npurpose described in such section.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(b) Negotiating Methodology and Objective.--\n            "),"(1) In general.--The Secretary shall develop and use a\nconsistent methodology for negotiations under subsection (a)\nthat, in accordance with paragraph (2) and subject to paragraph\n(3), achieves the lowest maximum fair price for each selected\ndrug while appropriately rewarding innovation.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(2) Prioritizing factors.--In considering the factors \n        described in subsection (d) in negotiating (and, as applicable, \n        renegotiating) the maximum fair price for a selected drug, the \n        Secretary shall, to the extent practicable, consider all of the \n        available factors listed but shall prioritize the following \n        factors:\n                    "),"(A) Research and development costs.--The factor\ndescribed in paragraph (1)(A) of subsection (d).\n",(0,i.kt)("inlineCode",{parentName:"p"},"(B) Market data.--The factor described in \n                paragraph (1)(B) of such subsection.\n                    "),"(C) Unit costs of production and distribution.--\nThe factor described in paragraph (1)(C) of such\nsubsection.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(D) Comparison to existing therapeutic \n                alternatives.--The factor described in paragraph (2)(A) \n                of such subsection.\n            "),"(3) Requirement.--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(A) In general.--In negotiating the maximum fair \n                price of a selected drug, with respect to an initial \n                price applicability year for the selected drug, and, as \n                applicable, in renegotiating the maximum fair price for \n                such drug, with respect to a subsequent year during the \n                price applicability period for such drug, in the case \n                that the manufacturer of the selected drug offers under \n                the negotiation or renegotiation, as applicable, a \n                price for such drug that is not more than the target \n                price described in subparagraph (B) for such drug for \n                the respective year, the Secretary shall agree under \n                such negotiation or renegotiation, respectively, to \n                such offered price as the maximum fair price.\n                    "),"(B) Target price.--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(i) In general.--Subject to clause (ii), \n                        the target price described in this subparagraph \n                        for a selected drug with respect to a year, is \n                        the average price (which shall be the net \n                        average price, if practicable, and volume-\n                        weighted, if practicable) for a unit of such \n                        drug for sales of such drug, as computed \n                        (across different dosage forms and strengths of \n                        the drug and not based on the specific \n                        formulation or package size or package type of \n                        the drug) in the applicable country described \n                        in section 1191(c)(3)(B) with respect to such \n                        drug that, with respect to such year, has the \n                        lowest average price for such drug as compared \n                        to the average prices (as so computed) of such \n                        drug with respect to such year in the other \n                        applicable countries described in such section \n                        with respect to such drug.\n                            "),"(ii) Selected drugs without aim price.--\nIn applying this paragraph in the case of\nnegotiating the maximum fair price of a\nselected drug for which there is no AIM price\navailable with respect to the initial price\napplicability year for such drug, or, as\napplicable, renegotiating the maximum fair\nprice for such drug with respect to a\nsubsequent year during the price applicability\nperiod for such drug before the first plan year\nfor which there is an AIM price available for\nsuch drug, the target price described in this\nsubparagraph for such drug and respective year\nis the amount that is 80 percent of the average\nmanufacturer price (as defined in section\n1927(k)(1)) for such drug and year.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(c) Limitation.--\n            "),"(1) In general.--Subject to paragraph (2), the maximum\nfair price negotiated (including as renegotiated) under this\nsection for a selected drug, with respect to each plan year\nduring a price applicability period for such drug, shall not\nexceed 120 percent of the AIM price applicable to such drug\nwith respect to such year.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(2) Selected drugs without aim price.--In the case of a \n        selected drug for which there is no AIM price available with \n        respect to the initial price applicability year for such drug, \n        for each plan year during the price applicability period before \n        the first plan year for which there is an AIM price available \n        for such drug, the maximum fair price negotiated (including as \n        renegotiated) under this section for the selected drug shall \n        not exceed the amount equal to 85 percent of the average \n        manufacturer price for the drug with respect to such year.\n    "),"(d) Considerations.--For purposes of negotiating and, as\napplicable, renegotiating (including for purposes of determining\nwhether to renegotiate) the maximum fair price of a selected drug under\nthis part with the manufacturer of the drug, the Secretary, consistent\nwith subsection (b)(2), shall take into consideration the factors\ndescribed in paragraphs (1), (2), (3), and (5), and may take into\nconsideration the factor described in paragraph (4):\n",(0,i.kt)("inlineCode",{parentName:"p"},"(1) Manufacturer-specific information.--The following \n        information, including as submitted by the manufacturer:\n                    "),"(A) Research and development costs of the\nmanufacturer for the drug and the extent to which the\nmanufacturer has recouped research and development\ncosts.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(B) Market data for the drug, including the \n                distribution of sales across different programs and \n                purchasers and projected future revenues for the drug.\n                    "),"(C) Unit costs of production and distribution of\nthe drug.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(D) Prior Federal financial support for novel \n                therapeutic discovery and development with respect to \n                the drug.\n                    "),"(E) Data on patents and on existing and pending\nexclusivity for the drug.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(F) National sales data for the drug.\n                    "),"(G) Information on clinical trials for the drug\nin the United States or in applicable countries\ndescribed in section 1191(c)(3)(B).\n",(0,i.kt)("inlineCode",{parentName:"p"},"(2) Information on alternative products.--The following \n        information:\n                    "),"(A) The extent to which the drug represents a\ntherapeutic advance as compared to existing therapeutic\nalternatives and, to the extent such information is\navailable, the costs of such existing therapeutic\nalternatives.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(B) Information on approval by the Food and Drug \n                Administration of alternative drug products.\n                    "),"(C) Information on comparative effectiveness\nanalysis for such products, taking into consideration\nthe effects of such products on specific populations,\nsuch as individuals with disabilities, the elderly,\nterminally ill, children, and other patient\npopulations.\nIn considering information described in subparagraph (C), the\nSecretary shall not use evidence or findings from comparative\nclinical effectiveness research in a manner that treats\nextending the life of an elderly, disabled, or terminally ill\nindividual as of lower value than extending the life of an\nindividual who is younger, nondisabled, or not terminally ill.\nNothing in the previous sentence shall affect the application\nor consideration of an AIM price for a selected drug.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(3) Foreign sales information.--To the extent available \n        on a timely basis, including as provided by a manufacturer of \n        the selected drug or otherwise, information on sales of the \n        selected drug in each of the countries described in section \n        1191(c)(3)(B).\n            "),"(4) VA drug pricing information.--Information disclosed\nto the Secretary pursuant to subsection (f).\n",(0,i.kt)("inlineCode",{parentName:"p"},"(5) Additional information.--Information submitted to the \n        Secretary, in accordance with a process specified by the \n        Secretary, by other parties that are affected by the \n        establishment of a maximum fair price for the selected drug.\n    "),"(e) Request for Information.--For purposes of negotiating and, as\napplicable, renegotiating (including for purposes of determining\nwhether to renegotiate) the maximum fair price of a selected drug under\nthis part with the manufacturer of the drug, with respect to a price\napplicability period, and other relevant data for purposes of this\nsection--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(1) the Secretary shall, not later than the selected drug \n        publication date with respect to the initial price \n        applicability year of such period, request drug pricing \n        information from the manufacturer of such selected drug, \n        including information described in subsection (d)(1); and\n            "),"(2) by not later than October 1 following the selected\ndrug publication date, the manufacturer of such selected drug\nshall submit to the Secretary such requested information in\nsuch form and manner as the Secretary may require.\nThe Secretary shall request, from the manufacturer or others, such\nadditional information as may be needed to carry out the negotiation\nand renegotiation process under this section.\n``(f) Disclosure of Information.--For purposes of this part, the\nSecretary of Veterans Affairs may disclose to the Secretary of Health\nand Human Services the price of any negotiation-eligible drug that is\npurchased pursuant to section 8126 of title 38, United States Code."),(0,i.kt)("p",null,"``SEC. 1195. PUBLICATION OF MAXIMUM FAIR PRICES."),(0,i.kt)("pre",null,(0,i.kt)("code",{parentName:"pre"},"``(a) In General.--With respect to an initial price applicability \n")),(0,i.kt)("p",null,"year and selected drug with respect to such year, not later than April\n1 of the plan year prior to such initial price applicability year, the\nSecretary shall publish in the Federal Register the maximum fair price\nfor such drug negotiated under this part with the manufacturer of such\ndrug.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(b) Updates.--\n            "),"(1) Subsequent year maximum fair prices.--For a selected\ndrug, for each plan year subsequent to the initial price\napplicability year for such drug with respect to which an\nagreement for such drug is in effect under section 1193, the\nSecretary shall publish in the Federal Register--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(A) subject to subparagraph (B), the amount equal \n                to the maximum fair price published for such drug for \n                the previous year, increased by the annual percentage \n                increase in the consumer price index for all urban \n                consumers (all items; U.S. city average) as of \n                September of such previous year; or\n                    "),"(B) in the case the maximum fair price for such\ndrug was renegotiated, for the first year for which\nsuch price as so renegotiated applies, such\nrenegotiated maximum fair price.\n``(2) Prices negotiated after deadline.--In the case of a\nselected drug with respect to an initial price applicability\nyear for which the maximum fair price is determined under this\npart after the date of publication under this section, the\nSecretary shall publish such maximum fair price in the Federal\nRegister by not later than 30 days after the date such maximum\nprice is so determined."),(0,i.kt)("p",null,"``SEC. 1196. ADMINISTRATIVE DUTIES; COORDINATION PROVISIONS."),(0,i.kt)("pre",null,(0,i.kt)("code",{parentName:"pre"},"``(a) Administrative Duties.--\n        ``(1) In general.--For purposes of section 1191, the \n    administrative duties described in this section are the \n    following:\n                ``(A) The establishment of procedures (including \n            through agreements with manufacturers under this part, \n            contracts with prescription drug plans under part D of \n            title XVIII and MA-PD plans under part C of such title, \n            and agreements under section 1197 with group health \n            plans and health insurance issuers of health insurance \n            coverage offered in the individual or group market) \n            under which the maximum fair price for a selected drug \n            is provided to fair price eligible individuals, who \n            with respect to such drug are described in subparagraph \n            (A) of section 1191(c)(1), at pharmacies or by mail \n            order service at the point-of-sale of the drug for the \n            applicable price period for such drug and providing \n            that such maximum fair price is used for determining \n            cost-sharing under such plans or coverage for the \n            selected drug.\n                ``(B) The establishment of procedures (including \n            through agreements with manufacturers under this part \n            and contracts with hospitals, physicians, and other \n            providers of services and suppliers and agreements \n            under section 1197 with group health plans and health \n            insurance issuers of health insurance coverage offered \n            in the individual or group market) under which, in the \n            case of a selected drug furnished or administered by \n            such a hospital, physician, or other provider of \n            services or supplier to fair price eligible individuals \n            (who with respect to such drug are described in \n            subparagraph (B) of section 1191(c)(1)), the maximum \n            fair price for the selected drug is provided to such \n            hospitals, physicians, and other providers of services \n            and suppliers (as applicable) with respect to such \n            individuals and providing that such maximum fair price \n            is used for determining cost-sharing under the \n            respective part, plan, or coverage for the selected \n            drug.\n                ``(C) The establishment of procedures (including \n            through agreements and contracts described in \n            subparagraphs (A) and (B)) to ensure that, not later \n            than 90 days after the dispensing of a selected drug to \n            a fair price eligible individual by a pharmacy or mail \n            order service, the pharmacy or mail order service is \n            reimbursed for an amount equal to the difference \n            between--\n                        ``(i) the lesser of--\n                                ``(I) the wholesale acquisition \n                            cost of the drug;\n                                ``(II) the national average drug \n                            acquisition cost of the drug; and\n                                ``(III) any other similar \n                            determination of pharmacy acquisition \n                            costs of the drug, as determined by the \n                            Secretary; and\n                        ``(ii) the maximum fair price for the drug.\n                ``(D) The establishment of procedures to ensure \n            that the maximum fair price for a selected drug is \n            applied before--\n                        ``(i) any coverage or financial assistance \n                    under other health benefit plans or programs \n                    that provide coverage or financial assistance \n                    for the purchase or provision of prescription \n                    drug coverage on behalf of fair price eligible \n                    individuals as the Secretary may specify; and\n                        ``(ii) any other discounts.\n                ``(E) The establishment of procedures to enter into \n            appropriate agreements and protocols for the ongoing \n            computation of AIM prices for selected drugs, \n            including, to the extent possible, to compute the AIM \n            price for selected drugs and including by providing \n            that the manufacturer of such a selected drug should \n            provide information for such computation not later than \n            3 months after the first date of the voluntary \n            negotiation period for such selected drug.\n                ``(F) The establishment of procedures to compute \n            and apply the maximum fair price across different \n            strengths and dosage forms of a selected drug and not \n            based on the specific formulation or package size or \n            package type of the drug.\n                ``(G) The establishment of procedures to negotiate \n            and apply the maximum fair price in a manner that does \n            not include any dispensing or similar fee.\n                ``(H) The establishment of procedures to carry out \n            the provisions of this part, as applicable, with \n            respect to--\n                        ``(i) fair price eligible individuals who \n                    are enrolled under a prescription drug plan \n                    under part D of title XVIII or an MA-PD plan \n                    under part C of such title;\n                        ``(ii) fair price eligible individuals who \n                    are enrolled under a group health plan or \n                    health insurance coverage offered by a health \n                    insurance issuer in the individual or group \n                    market with respect to which there is an \n                    agreement in effect under section 1197; and\n                        ``(iii) fair price eligible individuals who \n                    are entitled to benefits under part A of title \n                    XVIII or enrolled under part B of such title.\n                ``(I) The establishment of a negotiation process \n            and renegotiation process in accordance with section \n            1194, including a process for acquiring information \n            described in subsection (d) of such section and \n            determining amounts described in subsection (b) of such \n            section.\n                ``(J) The provision of a reasonable dispute \n            resolution mechanism to resolve disagreements between \n            manufacturers, fair price eligible individuals, and the \n            third party with a contract under subsection (c)(1).\n        ``(2) Monitoring compliance.--\n                ``(A) In general.--The Secretary shall monitor \n            compliance by a manufacturer with the terms of an \n            agreement under section 1193, including by establishing \n            a mechanism through which violations of such terms may \n            be reported.\n                ``(B) Notification.--If a third party with a \n            contract under subsection (c)(1) determines that the \n            manufacturer is not in compliance with such agreement, \n            the third party shall notify the Secretary of such \n            noncompliance for appropriate enforcement under section \n            4192 of the Internal Revenue Code of 1986 or section \n            1198, as applicable.\n``(b) Collection of Data.--\n        ``(1) From prescription drug plans and ma-pd plans.--The \n    Secretary may collect appropriate data from prescription drug \n    plans under part D of title XVIII and MA-PD plans under part C \n    of such title in a timeframe that allows for maximum fair \n    prices to be provided under this part for selected drugs.\n        ``(2) From health plans.--The Secretary may collect \n    appropriate data from group health plans or health insurance \n    issuers offering group or individual health insurance coverage \n    in a timeframe that allows for maximum fair prices to be \n    provided under this part for selected drugs.\n        ``(3) Coordination of data collection.--To the extent \n    feasible, as determined by the Secretary, the Secretary shall \n    ensure that data collected pursuant to this subsection is \n    coordinated with, and not duplicative of, other Federal data \n    collection efforts.\n``(c) Contract With Third Parties.--\n        ``(1) In general.--The Secretary may enter into a contract \n    with 1 or more third parties to administer the requirements \n    established by the Secretary in order to carry out this part. \n    At a minimum, the contract with a third party under the \n    preceding sentence shall require that the third party--\n                ``(A) receive and transmit information between the \n            Secretary, manufacturers, and other individuals or \n            entities the Secretary determines appropriate;\n                ``(B) receive, distribute, or facilitate the \n            distribution of funds of manufacturers to appropriate \n            individuals or entities in order to meet the \n            obligations of manufacturers under agreements under \n            this part;\n                ``(C) provide adequate and timely information to \n            manufacturers, consistent with the agreement with the \n            manufacturer under this part, as necessary for the \n            manufacturer to fulfill its obligations under this \n            part; and\n                ``(D) permit manufacturers to conduct periodic \n            audits, directly or through contracts, of the data and \n            information used by the third party to determine \n            discounts for applicable drugs of the manufacturer \n            under the program.\n        ``(2) Performance requirements.--The Secretary shall \n    establish performance requirements for a third party with a \n    contract under paragraph (1) and safeguards to protect the \n    independence and integrity of the activities carried out by the \n    third party under the program under this part.\n")),(0,i.kt)("p",null,"``SEC. 1197. VOLUNTARY PARTICIPATION BY OTHER HEALTH PLANS."),(0,i.kt)("pre",null,(0,i.kt)("code",{parentName:"pre"},"``(a) Agreement To Participate Under Program.--\n        ``(1) In general.--Subject to paragraph (2), under the \n    program under this part the Secretary shall be treated as \n    having in effect an agreement with a group health plan or \n    health insurance issuer offering group or individual health \n    insurance coverage (as such terms are defined in section 2791 \n    of the Public Health Service Act), with respect to a price \n    applicability period and a selected drug with respect to such \n    period--\n                ``(A) with respect to such selected drug furnished \n            or dispensed at a pharmacy or by mail order service if \n            coverage is provided under such plan or coverage during \n            such period for such selected drug as so furnished or \n            dispensed; and\n                ``(B) with respect to such selected drug furnished \n            or administered by a hospital, physician, or other \n            provider of services or supplier if coverage is \n            provided under such plan or coverage during such period \n            for such selected drug as so furnished or administered.\n        ``(2) Opting out of agreement.--The Secretary shall not be \n    treated as having in effect an agreement under the program \n    under this part with a group health plan or health insurance \n    issuer offering group or individual health insurance coverage \n    with respect to a price applicability period and a selected \n    drug with respect to such period if such a plan or issuer \n    affirmatively elects, through a process specified by the \n    Secretary, not to participate under the program with respect to \n    such period and drug.\n``(b) Publication of Election.--With respect to each price \n")),(0,i.kt)("p",null,"applicability period and each selected drug with respect to such\nperiod, the Secretary and the Secretary of Labor and the Secretary of\nthe Treasury, as applicable, shall make public a list of each group\nhealth plan and each health insurance issuer offering group or\nindividual health insurance coverage, with respect to which coverage is\nprovided under such plan or coverage for such drug, that has elected\nunder subsection (a) not to participate under the program with respect\nto such period and drug."),(0,i.kt)("p",null,"``SEC. 1198. CIVIL MONETARY PENALTY."),(0,i.kt)("pre",null,(0,i.kt)("code",{parentName:"pre"},"``(a) Violations Relating to Offering of Maximum Fair Price.--Any \n")),(0,i.kt)("p",null,"manufacturer of a selected drug that has entered into an agreement\nunder section 1193, with respect to a plan year during the price\napplicability period for such drug, that does not provide access to a\nprice that is not more than the maximum fair price (or a lesser price)\nfor such drug for such year--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(1) to a fair price eligible individual who with respect \n        to such drug is described in subparagraph (A) of section \n        1191(c)(1) and who is furnished or dispensed such drug during \n        such year; or\n            "),"(2) to a hospital, physician, or other provider of\nservices or supplier with respect to fair price eligible\nindividuals who with respect to such drug is described in\nsubparagraph (B) of such section and is furnished or\nadministered such drug by such hospital, physician, or provider\nor supplier during such year;\nshall be subject to a civil monetary penalty equal to ten times the\namount equal to the difference between the price for such drug made\navailable for such year by such manufacturer with respect to such\nindividual or hospital, physician, provider, or supplier and the\nmaximum fair price for such drug for such year.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(b) Violations of Certain Terms of Agreement.--Any manufacturer \nof a selected drug that has entered into an agreement under section \n1193, with respect to a plan year during the price applicability period \nfor such drug, that is in violation of a requirement imposed pursuant \nto section 1193(a)(6) shall be subject to a civil monetary penalty of \nnot more than $1,000,000 for each such violation.\n    "),"(c) Application.--The provisions of section 1128A (other than\nsubsections (a) and (b)) shall apply to a civil monetary penalty under\nthis section in the same manner as such provisions apply to a penalty\nor proceeding under section 1128A(a)."),(0,i.kt)("p",null,"``SEC. 1199. MISCELLANEOUS PROVISIONS."),(0,i.kt)("pre",null,(0,i.kt)("code",{parentName:"pre"},"``(a) Paperwork Reduction Act.--Chapter 35 of title 44, United \n")),(0,i.kt)("p",null,"States Code, shall not apply to data collected under this part.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(b) Limitation on Judicial Review.--The following shall not be \nsubject to judicial review:\n            "),"(1) The selection of drugs for publication under section\n1192(a).\n",(0,i.kt)("inlineCode",{parentName:"p"},"(2) The determination of whether a drug is a negotiation-\n        eligible drug under section 1192(d).\n            "),"(3) The determination of the maximum fair price of a\nselected drug under section 1194.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(4) The determination of units of a drug for purposes of \n        section 1191(c)(3).\n    "),"(c) Coordination.--In carrying out this part with respect to\ngroup health plans or health insurance coverage offered in the group\nmarket that are subject to oversight by the Secretary of Labor or the\nSecretary of the Treasury, the Secretary of Health and Human Services\nshall coordinate with such respective Secretary.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(d) Data Sharing.--The Secretary shall share with the Secretary \nof the Treasury such information as is necessary to determine the tax \nimposed by section 4192 of the Internal Revenue Code of 1986.''.\n    (b) Application of Maximum Fair Prices and Conforming Amendments.--\n            (1) Under medicare.--\n                    (A) Application to payments under part b.--Section \n                1847A(b)(1)(B) of the Social Security Act (42 U.S.C. \n                1395w-3a(b)(1)(B)) is amended by inserting "),"or in the\ncase of such a drug or biological that is a selected\ndrug (as defined in section 1192(c)), with respect to a\nprice applicability period (as defined in section\n1191(b)(2)), 106 percent of the maximum fair price (as\ndefined in section 1191(c)(2)) applicable for such drug\nand a plan year during such period'' after ",(0,i.kt)("inlineCode",{parentName:"p"},"paragraph \n                (4)''.\n                    (B) Exception to part d non-interference.--Section \n                1860D-11(i) of the Social Security Act (42 U.S.C. \n                1395w-111(i)) is amended by inserting "),", except as\nprovided under part E of title XI'' after ",(0,i.kt)("inlineCode",{parentName:"p"},"the \n                Secretary''.\n                    (C) Application as negotiated price under part d.--\n                Section 1860D-2(d)(1) of the Social Security Act (42 \n                U.S.C. 1395w-102(d)(1)) is amended--\n                            (i) in subparagraph (B), by inserting "),",\nsubject to subparagraph (D),'' after\n",(0,i.kt)("inlineCode",{parentName:"p"},"negotiated prices''; and\n                            (ii) by adding at the end the following new \n                        subparagraph:\n                    "),"(D) Application of maximum fair price for\nselected drugs.--In applying this section, in the case\nof a covered part D drug that is a selected drug (as\ndefined in section 1192(c)), with respect to a price\napplicability period (as defined in section\n1191(b)(2)), the negotiated prices used for payment (as\ndescribed in this subsection) shall be the maximum fair\nprice (as defined in section 1191(c)(2)) for such drug\nand for each plan year during such period.''.\n(D) Information from prescription drug plans and\nma-pd plans required.--\n(i) Prescription drug plans.--Section\n1860D-12(b) of the Social Security Act (42\nU.S.C. 1395w-112(b)) is amended by adding at\nthe end the following new paragraph:\n",(0,i.kt)("inlineCode",{parentName:"p"},"(8) Provision of information related to maximum fair \n        prices.--Each contract entered into with a PDP sponsor under \n        this part with respect to a prescription drug plan offered by \n        such sponsor shall require the sponsor to provide information \n        to the Secretary as requested by the Secretary in accordance \n        with section 1196(b).''.\n                            (ii) MA-PD plans.--Section 1857(f)(3) of \n                        the Social Security Act (42 U.S.C. 1395w-\n                        27(f)(3)) is amended by adding at the end the \n                        following new subparagraph:\n                    "),"(E) Provision of information related to maximum\nfair prices.--Section 1860D-12(b)(8).''.\n(2) Under group health plans and health insurance\ncoverage.--\n(A) PHSA.--Part D of title XXVII of the Public\nHealth Service Act (42 U.S.C. 300gg-111 et seq.) is\namended by adding at the end the following new section:"),(0,i.kt)("p",null,"``SEC. 2799A-11. FAIR PRICE NEGOTIATION PROGRAM AND APPLICATION OF\nMAXIMUM FAIR PRICES."),(0,i.kt)("pre",null,(0,i.kt)("code",{parentName:"pre"},"``(a) In General.--In the case of a group health plan or health \n")),(0,i.kt)("p",null,"insurance issuer offering group or individual health insurance coverage\nthat is treated under section 1197 of the Social Security Act as having\nin effect an agreement with the Secretary under the Fair Price\nNegotiation Program under part E of title XI of such Act, with respect\nto a price applicability period (as defined in section 1191(b) of such\nAct) and a selected drug (as defined in section 1192(c) of such Act)\nwith respect to such period with respect to which coverage is provided\nunder such plan or coverage--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(1) the provisions of such part shall apply--\n                    "),"(A) if coverage of such selected drug is provided\nunder such plan or coverage if the drug is furnished or\ndispensed at a pharmacy or by a mail order service, to\nthe plans or coverage offered by such plan or issuer,\nand to the individuals enrolled under such plans or\ncoverage, during such period, with respect to such\nselected drug, in the same manner as such provisions\napply to prescription drug plans and MA-PD plans, and\nto individuals enrolled under such prescription drug\nplans and MA-PD plans during such period; and\n",(0,i.kt)("inlineCode",{parentName:"p"},"(B) if coverage of such selected drug is provided \n                under such plan or coverage if the drug is furnished or \n                administered by a hospital, physician, or other \n                provider of services or supplier, to the plans or \n                coverage offered by such plan or issuers, to the \n                individuals enrolled under such plans or coverage, and \n                to hospitals, physicians, and other providers of \n                services and suppliers during such period, with respect \n                to such drug in the same manner as such provisions \n                apply to the Secretary, to individuals entitled to \n                benefits under part A of title XVIII or enrolled under \n                part B of such title, and to hospitals, physicians, and \n                other providers and suppliers participating under title \n                XVIII during such period;\n            "),"(2) the plan or issuer shall apply any cost-sharing\nresponsibilities under such plan or coverage, with respect to\nsuch selected drug, by substituting an amount not more than the\nmaximum fair price negotiated under such part E of title XI for\nsuch drug in lieu of the drug price upon which the cost-sharing\nwould have otherwise applied, and such cost-sharing\nresponsibilities with respect to such selected drug may not\nexceed such maximum fair price; and\n",(0,i.kt)("inlineCode",{parentName:"p"},"(3) the Secretary shall apply the provisions of such part \n        E to such plan, issuer, and coverage, such individuals so \n        enrolled in such plans and coverage, and such hospitals, \n        physicians, and other providers and suppliers participating in \n        such plans and coverage.\n    "),"(b) Notification Regarding Nonparticipation in Fair Price\nNegotiation Program.--A group health plan or a health insurance issuer\noffering group or individual health insurance coverage shall publicly\ndisclose in a manner and in accordance with a process specified by the\nSecretary any election made under section 1197 of the Social Security\nAct by the plan or issuer to not participate in the Fair Price\nNegotiation Program under part E of title XI of such Act with respect\nto a selected drug (as defined in section 1192(c) of such Act) for\nwhich coverage is provided under such plan or coverage before the\nbeginning of the plan year for which such election was made.''.\n(B) ERISA.--\n(i) In general.--Subpart B of part 7 of\nsubtitle B of title I of the Employee\nRetirement Income Security Act of 1974 (29\nU.S.C. 1181 et seq.) is amended by adding at\nthe end the following new section:"),(0,i.kt)("p",null,"``SEC. 726. FAIR PRICE NEGOTIATION PROGRAM AND APPLICATION OF MAXIMUM\nFAIR PRICES."),(0,i.kt)("pre",null,(0,i.kt)("code",{parentName:"pre"},"``(a) In General.--In the case of a group health plan or health \n")),(0,i.kt)("p",null,"insurance issuer offering group health insurance coverage that is\ntreated under section 1197 of the Social Security Act as having in\neffect an agreement with the Secretary under the Fair Price Negotiation\nProgram under part E of title XI of such Act, with respect to a price\napplicability period (as defined in section 1191(b) of such Act) and a\nselected drug (as defined in section 1192(c) of such Act) with respect\nto such period with respect to which coverage is provided under such\nplan or coverage--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(1) the provisions of such part shall apply, as \n        applicable--\n                    "),"(A) if coverage of such selected drug is provided\nunder such plan or coverage if the drug is furnished or\ndispensed at a pharmacy or by a mail order service, to\nthe plans or coverage offered by such plan or issuer,\nand to the individuals enrolled under such plans or\ncoverage, during such period, with respect to such\nselected drug, in the same manner as such provisions\napply to prescription drug plans and MA-PD plans, and\nto individuals enrolled under such prescription drug\nplans and MA-PD plans during such period; and\n",(0,i.kt)("inlineCode",{parentName:"p"},"(B) if coverage of such selected drug is provided \n                under such plan or coverage if the drug is furnished or \n                administered by a hospital, physician, or other \n                provider of services or supplier, to the plans or \n                coverage offered by such plan or issuers, to the \n                individuals enrolled under such plans or coverage, and \n                to hospitals, physicians, and other providers of \n                services and suppliers during such period, with respect \n                to such drug in the same manner as such provisions \n                apply to the Secretary, to individuals entitled to \n                benefits under part A of title XVIII or enrolled under \n                part B of such title, and to hospitals, physicians, and \n                other providers and suppliers participating under title \n                XVIII during such period;\n            "),"(2) the plan or issuer shall apply any cost-sharing\nresponsibilities under such plan or coverage, with respect to\nsuch selected drug, by substituting an amount not more than the\nmaximum fair price negotiated under such part E of title XI for\nsuch drug in lieu of the drug price upon which the cost-sharing\nwould have otherwise applied, and such cost-sharing\nresponsibilities with respect to such selected drug may not\nexceed such maximum fair price; and\n",(0,i.kt)("inlineCode",{parentName:"p"},"(3) the Secretary shall apply the provisions of such part \n        E to such plan, issuer, and coverage, and such individuals so \n        enrolled in such plans.\n    "),"(b) Notification Regarding Nonparticipation in Fair Price\nNegotiation Program.--A group health plan or a health insurance issuer\noffering group health insurance coverage shall publicly disclose in a\nmanner and in accordance with a process specified by the Secretary any\nelection made under section 1197 of the Social Security Act by the plan\nor issuer to not participate in the Fair Price Negotiation Program\nunder part E of title XI of such Act with respect to a selected drug\n(as defined in section 1192(c) of such Act) for which coverage is\nprovided under such plan or coverage before the beginning of the plan\nyear for which such election was made.''.\n(ii) Application to retiree and certain\nsmall group health plans.--Section 732(a) of\nthe Employee Retirement Income Security Act of\n1974 (29 U.S.C. 1191a(a)) is amended by\nstriking ",(0,i.kt)("inlineCode",{parentName:"p"},"section 711'' and inserting \n                        "),"sections 711 and 726''.\n(iii) Clerical amendment.--The table of\nsections for subpart B of part 7 of subtitle B\nof title I of the Employee Retirement Income\nSecurity Act of 1974 is amended by adding at\nthe end the following:"),(0,i.kt)("p",null,"``Sec. 726. Fair Price Negotiation Program and application of maximum\nfair prices.''.\n(C) IRC.--\n(i) In general.--Subchapter B of chapter\n100 of the Internal Revenue Code of 1986 is\namended by adding at the end the following new\nsection:"),(0,i.kt)("p",null,"``SEC. 9826. FAIR PRICE NEGOTIATION PROGRAM AND APPLICATION OF MAXIMUM\nFAIR PRICES."),(0,i.kt)("pre",null,(0,i.kt)("code",{parentName:"pre"},"``(a) In General.--In the case of a group health plan that is \n")),(0,i.kt)("p",null,"treated under section 1197 of the Social Security Act as having in\neffect an agreement with the Secretary under the Fair Price Negotiation\nProgram under part E of title XI of such Act, with respect to a price\napplicability period (as defined in section 1191(b) of such Act) and a\nselected drug (as defined in section 1192(c) of such Act) with respect\nto such period with respect to which coverage is provided under such\nplan--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(1) the provisions of such part shall apply, as \n        applicable--\n                    "),"(A) if coverage of such selected drug is provided\nunder such plan if the drug is furnished or dispensed\nat a pharmacy or by a mail order service, to the plan,\nand to the individuals enrolled under such plan during\nsuch period, with respect to such selected drug, in the\nsame manner as such provisions apply to prescription\ndrug plans and MA-PD plans, and to individuals enrolled\nunder such prescription drug plans and MA-PD plans\nduring such period; and\n",(0,i.kt)("inlineCode",{parentName:"p"},"(B) if coverage of such selected drug is provided \n                under such plan if the drug is furnished or \n                administered by a hospital, physician, or other \n                provider of services or supplier, to the plan, to the \n                individuals enrolled under such plan, and to hospitals, \n                physicians, and other providers of services and \n                suppliers during such period, with respect to such drug \n                in the same manner as such provisions apply to the \n                Secretary, to individuals entitled to benefits under \n                part A of title XVIII or enrolled under part B of such \n                title, and to hospitals, physicians, and other \n                providers and suppliers participating under title XVIII \n                during such period;\n            "),"(2) the plan shall apply any cost-sharing\nresponsibilities under such plan, with respect to such selected\ndrug, by substituting an amount not more than the maximum fair\nprice negotiated under such part E of title XI for such drug in\nlieu of the drug price upon which the cost-sharing would have\notherwise applied, and such cost-sharing responsibilities with\nrespect to such selected drug may not exceed such maximum fair\nprice; and\n",(0,i.kt)("inlineCode",{parentName:"p"},"(3) the Secretary shall apply the provisions of such part \n        E to such plan and such individuals so enrolled in such plan.\n    "),"(b) Notification Regarding Nonparticipation in Fair Price\nNegotiation Program.--A group health plan shall publicly disclose in a\nmanner and in accordance with a process specified by the Secretary any\nelection made under section 1197 of the Social Security Act by the plan\nto not participate in the Fair Price Negotiation Program under part E\nof title XI of such Act with respect to a selected drug (as defined in\nsection 1192(c) of such Act) for which coverage is provided under such\nplan before the beginning of the plan year for which such election was\nmade.''.\n(ii) Application to retiree and certain\nsmall group health plans.--Section 9831(a)(2)\nof the Internal Revenue Code of 1986 is amended\nby inserting ",(0,i.kt)("inlineCode",{parentName:"p"},"other than with respect to \n                        section 9826,'' before "),"any group health\nplan''.\n(iii) Clerical amendment.--The table of\nsections for subchapter B of chapter 100 of\nsuch Code is amended by adding at the end the\nfollowing new item:"),(0,i.kt)("p",null,(0,i.kt)("inlineCode",{parentName:"p"},"Sec. 9826. Fair Price Negotiation Program and application of maximum \n                            fair prices.''.\n            (3) Fair price negotiation program prices included in best \n        price and amp.--Section 1927 of the Social Security Act (42 \n        U.S.C. 1396r-8) is amended--\n                    (A) in subsection (c)(1)(C)(ii)--\n                            (i) in subclause (III), by striking at the \n                        end "),"; and'';\n(ii) in subclause (IV), by striking at the\nend the period and inserting ",(0,i.kt)("inlineCode",{parentName:"p"},"; and''; and\n                            (iii) by adding at the end the following \n                        new subclause:\n                                    "),"(V) in the case of a rebate\nperiod and a covered outpatient drug\nthat is a selected drug (as defined in\nsection 1192(c)) during such rebate\nperiod, shall be inclusive of the price\nfor such drug made available from the\nmanufacturer during the rebate period\nby reason of application of part E of\ntitle XI to any wholesaler, retailer,\nprovider, health maintenance\norganization, nonprofit entity, or\ngovernmental entity within the United\nStates.''; and\n(B) in subsection (k)(1)(B), by adding at the end\nthe following new clause:\n",(0,i.kt)("inlineCode",{parentName:"p"},"(iii) Clarification.--Notwithstanding \n                        clause (i), in the case of a rebate period and \n                        a covered outpatient drug that is a selected \n                        drug (as defined in section 1192(c)) during \n                        such rebate period, any reduction in price paid \n                        during the rebate period to the manufacturer \n                        for the drug by a wholesaler or retail \n                        community pharmacy described in subparagraph \n                        (A) by reason of application of part E of title \n                        XI shall be included in the average \n                        manufacturer price for the covered outpatient \n                        drug.''.\n            (4) FEHBP.--Section 8902 of title 5, United States Code, is \n        amended by adding at the end the following:\n    "),"(p) A contract may not be made or a plan approved under this\nchapter with any carrier that has affirmatively elected, pursuant to\nsection 1197 of the Social Security Act, not to participate in the Fair\nPrice Negotiation Program established under section 1191 of such Act\nfor any selected drug (as that term is defined in section 1192(c) of\nsuch Act).''.\n(5) Option of secretary of veterans affairs to purchase\ncovered drugs at maximum fair prices.--Section 8126 of title\n38, United States Code, is amended--\n(A) in subsection (a)(2), by inserting ",(0,i.kt)("inlineCode",{parentName:"p"},", subject \n                to subsection (j),'' after "),"may not exceed'';\n(B) in subsection (d), in the matter preceding\nparagraph (1), by inserting ",(0,i.kt)("inlineCode",{parentName:"p"},", subject to subsection \n                (j)'' after "),"for the procurement of the drug''; and\n(C) by adding at the end the following new\nsubsection:\n",(0,i.kt)("inlineCode",{parentName:"p"},"(j)(1) In the case of a covered drug that is a selected drug, for \nany year during the price applicability period for such drug, if the \nSecretary determines that the maximum fair price of such drug for such \nyear is less than the price for such drug otherwise in effect pursuant \nto this section (including after application of any reduction under \nsubsection (a)(2) and any discount under subsection (c)), at the option \nof the Secretary, in lieu of the maximum price (determined after \napplication of the reduction under subsection (a)(2) and any discount \nunder subsection (c), as applicable) that would be permitted to be \ncharged during such year for such drug pursuant to this section without \napplication of this subsection, the maximum price permitted to be \ncharged during such year for such drug pursuant to this section shall \nbe such maximum fair price for such drug and year.\n    "),"(2) For purposes of this subsection:\n",(0,i.kt)("inlineCode",{parentName:"p"},"(A) The term `maximum fair price' means, with respect to \n        a selected drug and year during the price applicability period \n        for such drug, the maximum fair price (as defined in section \n        1191(c)(2) of the Social Security Act) for such drug and year.\n            "),"(B) The term ",(0,i.kt)("inlineCode",{parentName:"p"},"negotiation eligible drug' has the meaning \n        given such term in section 1192(d)(1) of the Social Security \n        Act.\n            ``(C) The term "),"price applicability period' has, with\nrespect to a selected drug, the meaning given such term in\nsection 1191(b)(2) of such Act.\n`",(0,i.kt)("inlineCode",{parentName:"p"},"(D) The term "),"selected drug' means, with respect to a\nyear, a drug that is a selected drug under section 1192(c) of\nsuch Act for such year.''."),(0,i.kt)("p",null,"SEC. 139002. SELECTED DRUG MANUFACTURER EXCISE TAX IMPOSED DURING\nNONCOMPLIANCE PERIODS."),(0,i.kt)("pre",null,(0,i.kt)("code",{parentName:"pre"},"(a) In General.--Subchapter E of chapter 32 of the Internal Revenue \n")),(0,i.kt)("p",null,"Code of 1986 is amended by adding at the end the following new section:"),(0,i.kt)("p",null,"``SEC. 4192. SELECTED DRUGS DURING NONCOMPLIANCE PERIODS."),(0,i.kt)("pre",null,(0,i.kt)("code",{parentName:"pre"},"``(a) In General.--There is hereby imposed on the sale by the \n")),(0,i.kt)("p",null,"manufacturer, producer, or importer of any selected drug during a day\ndescribed in subsection (b) a tax in an amount such that the applicable\npercentage is equal to the ratio of--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(1) such tax, divided by\n            "),"(2) the sum of such tax and the price for which so sold.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(b) Noncompliance Periods.--A day is described in this subsection \nwith respect to a selected drug if it is a day during one of the \nfollowing periods:\n            "),"(1) The period beginning on the June 16th immediately\nfollowing the selected drug publication date and ending on the\nfirst date during which the manufacturer of the drug has in\nplace an agreement described in subsection (a) of section 1193\nof the Social Security Act with respect to such drug.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(2) The period beginning on the April 1st immediately \n        following the June 16th described in paragraph (1) and ending \n        on the first date during which the manufacturer of the drug has \n        agreed to a maximum fair price under such agreement.\n            "),"(3) In the case of a selected drug with respect to which\nthe Secretary of Health and Human Services has specified a\nrenegotiation period under such agreement, the period beginning\non the first date after the last date of such renegotiation\nperiod and ending on the first date during which the\nmanufacturer of the drug has agreed to a renegotiated maximum\nfair price under such agreement.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(4) With respect to information that is required to be \n        submitted to the Secretary of Health and Human Services under \n        such agreement, the period beginning on the date on which such \n        Secretary certifies that such information is overdue and ending \n        on the date that such information is so submitted.\n            "),"(5) In the case of a selected drug with respect to which\na payment is due under subsection (c) of such section 1193, the\nperiod beginning on the date on which the Secretary of Health\nand Human Services certifies that such payment is overdue and\nending on the date that such payment is made in full.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(c) Applicable Percentage.--For purposes of this section, the \nterm `applicable percentage' means--\n            "),"(1) in the case of sales of a selected drug during the\nfirst 90 days described in subsection (b) with respect to such\ndrug, 65 percent,\n",(0,i.kt)("inlineCode",{parentName:"p"},"(2) in the case of sales of such drug during the 91st day \n        through the 180th day described in subsection (b) with respect \n        to such drug, 75 percent,\n            "),"(3) in the case of sales of such drug during the 181st\nday through the 270th day described in subsection (b) with\nrespect to such drug, 85 percent, and\n",(0,i.kt)("inlineCode",{parentName:"p"},"(4) in the case of sales of such drug during any \n        subsequent day, 95 percent.\n    "),"(d) Selected Drug.--For purposes of this section--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(1) In general.--The term `selected drug' means any \n        selected drug (within the meaning of section 1192 of the Social \n        Security Act) which is manufactured or produced in the United \n        States or entered into the United States for consumption, use, \n        or warehousing.\n            "),"(2) United states.--The term ",(0,i.kt)("inlineCode",{parentName:"p"},"United States' has the \n        meaning given such term by section 4612(a)(4).\n            ``(3) Coordination with rules for possessions of the united \n        states.--Rules similar to the rules of paragraphs (2) and (4) \n        of section 4132(c) shall apply for purposes of this section.\n    ``(e) Other Definitions.--For purposes of this section, the terms \n"),"selected drug publication date' and `maximum fair price' have the\nmeaning given such terms in section 1191 of the Social Security Act.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(f) Anti-Abuse Rule.--In the case of a sale which was timed for \nthe purpose of avoiding the tax imposed by this section, the Secretary \nmay treat such sale as occurring during a day described in subsection \n(b).''.\n    (b) No Deduction for Excise Tax Payments.--Section 275 of the \nInternal Revenue Code of 1986 is amended by adding "),"or by section\n4192'' before the period at the end of subsection (a)(6).\n(c) Conforming Amendments.--\n(1) Section 4221(a) of the Internal Revenue Code of 1986 is\namended by inserting ",(0,i.kt)("inlineCode",{parentName:"p"},"or 4192'' after "),"section 4191''.\n(2) Section 6416(b)(2) of such Code is amended by inserting\n",(0,i.kt)("inlineCode",{parentName:"p"},"or 4192'' after "),"section 4191''.\n(d) Clerical Amendments.--\n(1) The heading of subchapter E of chapter 32 of the\nInternal Revenue Code of 1986 is amended by striking ",(0,i.kt)("inlineCode",{parentName:"p"},"Medical \n        Devices'' and inserting "),"Other Medical Products''.\n(2) The table of subchapters for chapter 32 of such Code is\namended by striking the item relating to subchapter E and\ninserting the following new item:"),(0,i.kt)("pre",null,(0,i.kt)("code",{parentName:"pre"},"           ``subchapter e. other medical products''.\n\n        (3) The table of sections for subchapter E of chapter 32 of \n    such Code is amended by adding at the end the following new \n    item:\n")),(0,i.kt)("p",null,"``Sec. 4192. Selected drugs during noncompliance periods.''.\n(e) Effective Date.--The amendments made by this section shall\napply to sales after the date of the enactment of this Act."),(0,i.kt)("p",null,"SEC. 139003. FAIR PRICE NEGOTIATION IMPLEMENTATION FUND."),(0,i.kt)("pre",null,(0,i.kt)("code",{parentName:"pre"},"(a) In General.--There is hereby established a Fair Price \n")),(0,i.kt)("p",null,"Negotiation Implementation Fund (referred to in this section as the\n``Fund''). The Secretary of Health and Human Services may obligate and\nexpend amounts in the Fund to carry out this part and parts 2 and 3\n(and the amendments made by such parts).\n(b) Funding.--There is authorized to be appropriated, and there is\nhereby appropriated, out of any monies in the Treasury not otherwise\nappropriated, to the Fund $3,000,000,000, to remain available until\nexpended, of which--\n(1) $600,000,000 shall become available on the date of the\nenactment of this Act;\n(2) $600,000,000 shall become available on October 1, 2023;\n(3) $600,000,000 shall become available on October 1, 2024;\n(4) $600,000,000 shall become available on October 1, 2025;\nand\n(5) $600,000,000 shall become available on October 1, 2026.\n(c) Supplement Not Supplant.--Any amounts appropriated pursuant to\nthis section shall be in addition to any other amounts otherwise\nappropriated pursuant to any other provision of law."),(0,i.kt)("pre",null,(0,i.kt)("code",{parentName:"pre"},"          PART 2--PRESCRIPTION DRUG INFLATION REBATES\n")),(0,i.kt)("p",null,"SEC. 139101. MEDICARE PART B REBATE BY MANUFACTURERS."),(0,i.kt)("pre",null,(0,i.kt)("code",{parentName:"pre"},"(a) In General.--Section 1834 of the Social Security Act (42 U.S.C. \n")),(0,i.kt)("p",null,"1395m) is amended by adding at the end the following new subsection:\n",(0,i.kt)("inlineCode",{parentName:"p"},"(z) Rebate by Manufacturers for Single Source Drugs With Prices \nIncreasing Faster Than Inflation.--\n            "),"(1) Requirements.--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(A) Secretarial provision of information.--Not \n                later than 6 months after the end of each calendar \n                quarter beginning on or after July 1, 2023, the \n                Secretary shall, for each part B rebatable drug, report \n                to each manufacturer of such part B rebatable drug the \n                following for such calendar quarter:\n                            "),"(i) Information on the total number of\nunits of the billing and payment code described\nin subparagraph (A)(i) of paragraph (3) with\nrespect to such drug and calendar quarter.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(ii) Information on the amount (if any) \n                        of the excess average sales price increase \n                        described in subparagraph (A)(ii) of such \n                        paragraph for such drug and calendar quarter.\n                            "),"(iii) The rebate amount specified under\nsuch paragraph for such part B rebatable drug\nand calendar quarter.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(B) Manufacturer requirement.--For each calendar \n                quarter beginning on or after July 1, 2023, the \n                manufacturer of a part B rebatable drug shall, for such \n                drug, not later than 30 days after the date of receipt \n                from the Secretary of the information described in \n                subparagraph (A) for such calendar quarter, provide to \n                the Secretary a rebate that is equal to the amount \n                specified in paragraph (3) for such drug for such \n                calendar quarter.\n            "),"(2) Part b rebatable drug defined.--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(A) In general.--In this subsection, the term \n                `part B rebatable drug' means a single source drug or \n                biological (as defined in subparagraph (D) of section \n                1847A(c)(6)), including a biosimilar biological product \n                (as defined in subparagraph (H) of such section), \n                payable (if such drug were furnished to an individual \n                enrolled under this part) under this part, except such \n                term shall not include such a drug or biological--\n                            "),"(i) if the average total allowed charges\nunder this part as determined by the Secretary\nfor a year per individual that uses such a drug\nor biological, as determined by the Secretary,\nare less than, subject to subparagraph (B),\n$100; or\n",(0,i.kt)("inlineCode",{parentName:"p"},"(ii) that is a vaccine described in \n                        subparagraph (A) or (B) of section 1861(s)(10).\n                    "),"(B) Increase.--The dollar amount applied under\nsubparagraph (A)(i)--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(i) for 2024, shall be the dollar amount \n                        specified under such subparagraph for 2023, \n                        increased by the percentage increase in the \n                        consumer price index for all urban consumers \n                        (United States city average) for the 12-month \n                        period ending with June of the previous year; \n                        and\n                            "),"(ii) for a subsequent year, shall be the\ndollar amount specified in this clause (or\nclause (i)) for the previous year, increased by\nthe percentage increase in the consumer price\nindex for all urban consumers (United States\ncity average) for the 12-month period ending\nwith June of the previous year.\nAny dollar amount specified under this subparagraph\nthat is not a multiple of $10 shall be rounded to the\nnearest multiple of $10.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(3) Rebate amount.--\n                    "),"(A) In general.--For purposes of paragraph (1),\nthe amount specified in this paragraph for a part B\nrebatable drug assigned to a billing and payment code\nfor a calendar quarter is, subject to subparagraph (B)\nand paragraph (4), the amount equal to the product of--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(i) the total number of units, as \n                        described in section 1847A(c)(1)(B), with \n                        respect to such drug during the calendar \n                        quarter; and\n                            "),"(ii) the amount (if any) by which--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(I) the payment amount under \n                                subparagraph (B) or (C) of section \n                                1847A(b)(1), as applicable, for such \n                                part B rebatable drug during the \n                                calendar quarter; exceeds\n                                    "),"(II) the inflation-adjusted\npayment amount determined under\nsubparagraph (C) for such part B\nrebatable drug during the calendar\nquarter.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(B) Excluded units.--For purposes of subparagraph \n                (A)(i), the Secretary shall exclude from the total \n                number of units with respect to a part B rebatable drug \n                and calendar quarter units of such part B rebatable \n                drug for which payment was made under a State plan \n                under title XIX (or waiver of such plan), as reported \n                by States under section 1927(b)(2)(A) for the most \n                recent rebate period.\n                    "),"(C) Determination of inflation-adjusted payment\namount.--The inflation-adjusted payment amount\ndetermined under this subparagraph for a part B\nrebatable drug for a calendar quarter is--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(i) the payment amount for the billing \n                        and payment code for such drug in the payment \n                        amount benchmark quarter (as defined in \n                        subparagraph (D)); increased by\n                            "),"(ii) the percentage by which the rebate\nperiod CPI-U (as defined in subparagraph (F))\nfor the calendar quarter exceeds the benchmark\nperiod CPI-U (as defined in subparagraph (E)).\n",(0,i.kt)("inlineCode",{parentName:"p"},"(D) Payment amount benchmark quarter.--The term \n                `payment amount benchmark quarter' means the calendar \n                quarter beginning January 1, 2016.\n                    "),"(E) Benchmark period cpi-u.--The term ",(0,i.kt)("inlineCode",{parentName:"p"},"benchmark \n                period CPI-U' means the consumer price index for all \n                urban consumers (United States city average) for July \n                2015.\n                    ``(F) Rebate period cpi-u.--The term "),"rebate period\nCPI-U' means, with respect to a calendar quarter\ndescribed in subparagraph (C), the greater of the\nbenchmark period CPI-U and the consumer price index for\nall urban consumers (United States city average) for\nthe first month of the calendar quarter that is two\ncalendar quarters prior to such described calendar\nquarter.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(4) Special treatment of certain drugs and exemption.--\n                    "),"(A) Subsequently approved drugs.--Subject to\nsubparagraph (B), in the case of a part B rebatable\ndrug first approved or licensed by the Food and Drug\nAdministration after July 1, 2015, clause (i) of\nparagraph (3)(C) shall be applied as if the term\n",(0,i.kt)("inlineCode",{parentName:"p"},"payment amount benchmark quarter' were defined under \n                paragraph (3)(D) as the third full calendar quarter \n                after the day on which the drug was first marketed and \n                clause (ii) of paragraph (3)(C) shall be applied as if \n                the term "),"benchmark period CPI-U' were defined under\nparagraph (3)(E) as if the reference to ",(0,i.kt)("inlineCode",{parentName:"p"},"July 2015' \n                under such paragraph were a reference to "),"the first\nmonth of the first full calendar quarter after the day\non which the drug was first marketed'.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(B) Timeline for provision of rebates for \n                subsequently approved drugs.--In the case of a part B \n                rebatable drug first approved or licensed by the Food \n                and Drug Administration after July 1, 2015, paragraph \n                (1)(B) shall be applied as if the reference to `July 1, \n                2023' under such paragraph were a reference to the \n                later of the 6th full calendar quarter after the day on \n                which the drug was first marketed or July 1, 2023.\n                    "),"(C) Exemption for shortages.--The Secretary may\nreduce or waive the rebate amount under paragraph\n(1)(B) with respect to a part B rebatable drug that is\ndescribed as currently in shortage on the shortage list\nin effect under section 506E of the Federal Food, Drug,\nand Cosmetic Act or in the case of other exigent\ncircumstances, as determined by the Secretary.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(D) Selected drugs.--In the case of a part B \n                rebatable drug that is a selected drug (as defined in \n                section 1192(c)) for a price applicability period (as \n                defined in section 1191(b)(2))--\n                            "),"(i) for calendar quarters during such\nperiod for which a maximum fair price (as\ndefined in section 1191(c)(2)) for such drug\nhas been determined and is applied under part E\nof title XI, the rebate amount under paragraph\n(1)(B) shall be waived; and\n",(0,i.kt)("inlineCode",{parentName:"p"},"(ii) in the case such drug is determined \n                        (pursuant to such section 1192(c)) to no longer \n                        be a selected drug, for each applicable year \n                        beginning after the price applicability period \n                        with respect to such drug, clause (i) of \n                        paragraph (3)(C) shall be applied as if the \n                        term `payment amount benchmark quarter' were \n                        defined under paragraph (3)(D) as the calendar \n                        quarter beginning January 1 of the last year \n                        beginning during such price applicability \n                        period with respect to such selected drug and \n                        clause (ii) of paragraph (3)(C) shall be \n                        applied as if the term `benchmark period CPI-U' \n                        were defined under paragraph (3)(E) as if the \n                        reference to `July 2015' under such paragraph \n                        were a reference to the July of the year \n                        preceding such last year.\n            "),"(5) Application to beneficiary coinsurance.--In the case\nof a part B rebatable drug, if the payment amount under this\npart for a quarter exceeds the inflation adjusted payment for\nsuch quarter--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(A) in computing the amount of any coinsurance \n                applicable under this part to an individual to whom \n                such drug is furnished, the computation of such \n                coinsurance shall be based on the inflation-adjusted \n                payment amount determined under paragraph (3)(C) for \n                such part B rebatable drug; and\n                    "),"(B) the amount of such coinsurance is equal to 20\npercent of such inflation-adjusted payment amount so\ndetermined.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(6) Rebate deposits.--Amounts paid as rebates under \n        paragraph (1)(B) shall be deposited into the Federal \n        Supplementary Medical Insurance Trust Fund established under \n        section 1841.\n            "),"(7) Civil money penalty.--If a manufacturer of a part B\nrebatable drug has failed to comply with the requirements under\nparagraph (1)(B) for such drug for a calendar quarter, the\nmanufacturer shall be subject to, in accordance with a process\nestablished by the Secretary pursuant to regulations, a civil\nmoney penalty in an amount equal to at least 125 percent of the\namount specified in paragraph (3) for such drug for such\ncalendar quarter. The provisions of section 1128A (other than\nsubsections (a) (with respect to amounts of penalties or\nadditional assessments) and (b)) shall apply to a civil money\npenalty under this paragraph in the same manner as such\nprovisions apply to a penalty or proceeding under section\n1128A(a).\n",(0,i.kt)("inlineCode",{parentName:"p"},"(8) Application to multiple source drugs.--The Secretary \n        may, pursuant to rulemaking, apply the provisions of this \n        subsection to multiple source drugs (as defined in section \n        1847A(c)(6)(C)), including, for purposes of determining the \n        rebate amount under paragraph (3), by calculating manufacturer-\n        specific average sales prices for the benchmark period and the \n        rebate period.''.\n    (b) Amounts Payable; Cost-Sharing.--Section 1833 of the Social \nSecurity Act (42 U.S.C. 1395l) is amended--\n            (1) in subsection (a)--\n                    (A) in paragraph (1)--\n                            (i) in subparagraph (G), by inserting "),",\nsubject to subsection (i)(9),'' after ",(0,i.kt)("inlineCode",{parentName:"p"},"the \n                        amounts paid'';\n                            (ii) in subparagraph (S), by striking \n                        "),"with respect to'' and inserting ",(0,i.kt)("inlineCode",{parentName:"p"},"subject to \n                        subparagraph (DD), with respect to'';\n                            (iii) by striking "),"and (DD)'' and\ninserting ",(0,i.kt)("inlineCode",{parentName:"p"},"(EE)''; and\n                            (iv) by inserting before the semicolon at \n                        the end the following: "),", and (EE) with\nrespect to a part B rebatable drug (as defined\nin paragraph (2) of section 1834(z)) for which\nthe payment amount for a calendar quarter under\nparagraph (3)(A)(ii)(I) of such section for\nsuch quarter exceeds the inflation-adjusted\npayment under paragraph (3)(A)(ii)(II) of such\nsection for such quarter, the amounts paid\nshall be the difference between (i) the payment\namount under paragraph (3)(A)(ii)(I) of such\nsection for such drug, and (ii) 20 percent of\nthe inflation-adjusted payment amount under\nparagraph (3)(A)(ii)(II) of such section for\nsuch drug''; and\n(B) by adding at the end of the flush left matter\nfollowing paragraph (9), the following:\n",(0,i.kt)("inlineCode",{parentName:"p"},"For purposes of applying paragraph (1)(EE), subsections (i)(9) and \n(t)(8)(F), and section 1834(z)(5), the Secretary shall make such \nestimates and use such data as the Secretary determines appropriate, \nand may do so by program instruction or otherwise.'';\n            (2) in subsection (i), by adding at the end the following \n        new paragraph:\n    "),"(9) In the case of a part B rebatable drug (as defined in\nparagraph (2) of section 1834(z)) for which payment under this\nsubsection is not packaged into a payment for a covered OPD service (as\ndefined in subsection (t)(1)(B)) (or group of services) furnished on or\nafter July 1, 2023, under the system under this subsection, in lieu of\ncalculation of coinsurance and the amount of payment otherwise\napplicable under this subsection, the provisions of section 1834(z)(5),\nparagraph (1)(EE) of subsection (a), and the flush left matter\nfollowing paragraph (9) of subsection (a), shall, as determined\nappropriate by the Secretary, apply under this subsection in the same\nmanner as such provisions of section 1834(z)(5) and subsection (a)\napply under such section and subsection.''; and\n(3) in subsection (t)(8), by adding at the end the\nfollowing new subparagraph:\n",(0,i.kt)("inlineCode",{parentName:"p"},"(F) Part b rebatable drugs.--In the case of a \n                part B rebatable drug (as defined in paragraph (2) of \n                section 1834(z)) for which payment under this part is \n                not packaged into a payment for a service furnished on \n                or after July 1, 2023, under the system under this \n                subsection, in lieu of calculation of coinsurance and \n                the amount of payment otherwise applicable under this \n                subsection, the provisions of section 1834(z)(5), \n                paragraph (1)(EE) of subsection (a), and the flush left \n                matter following paragraph (9) of subsection (a), \n                shall, as determined appropriate by the Secretary, \n                apply under this subsection in the same manner as such \n                provisions of section 1834(z)(5) and subsection (a) \n                apply under such section and subsection.''.\n    (c) Conforming Amendments.--\n            (1) To part b asp calculation.--Section 1847A(c)(3) of the \n        Social Security Act (42 U.S.C. 1395w-3a(c)(3)) is amended by \n        inserting "),"or section 1834(z)'' after ",(0,i.kt)("inlineCode",{parentName:"p"},"section 1927''.\n            (2) Excluding parts b drug inflation rebate from best \n        price.--Section 1927(c)(1)(C)(ii)(I) of the Social Security Act \n        (42 U.S.C. 1396r-8(c)(1)(C)(ii)(I)) is amended by inserting \n        "),"or section 1834(z)'' after ",(0,i.kt)("inlineCode",{parentName:"p"},"this section''.\n            (3) Coordination with medicaid rebate information \n        disclosure.--Section 1927(b)(3)(D)(i) of the Social Security \n        Act (42 U.S.C. 1396r-8(b)(3)(D)(i)) is amended by striking "),"or\nto carry out section 1847B'' and inserting ``to carry out\nsection 1847B or section 1834(z)''."),(0,i.kt)("p",null,"SEC. 139102. MEDICARE PART D REBATE BY MANUFACTURERS."),(0,i.kt)("pre",null,(0,i.kt)("code",{parentName:"pre"},"(a) In General.--Part D of title XVIII of the Social Security Act \n")),(0,i.kt)("p",null,"is amended by inserting after section 1860D-14A (42 U.S.C. 1395w-114a)\nthe following new section:"),(0,i.kt)("p",null,"``SEC. 1860D-14B. MANUFACTURER REBATE FOR CERTAIN DRUGS WITH PRICES\nINCREASING FASTER THAN INFLATION."),(0,i.kt)("pre",null,(0,i.kt)("code",{parentName:"pre"},"``(a) Requirements.--\n        ``(1) Secretarial provision of information.--Not later than \n    9 months after the end of each applicable year (as defined in \n    subsection (g)(7)), the Secretary shall, for each part D \n    rebatable drug, report to each manufacturer of such part D \n    rebatable drug the following for such year:\n                ``(A) Information on the amount (if any) of the \n            excess average manufacturer price increase described in \n            subsection (b)(1)(B) for each dosage form and strength \n            with respect to such drug and year.\n                ``(B) The rebate amount specified under subsection \n            (b) for each dosage form and strength with respect to \n            such drug and year.\n        ``(2) Manufacturer requirements.--For each applicable year, \n    the manufacturer of a part D rebatable drug, for each dosage \n    form and strength with respect to such drug, not later than 30 \n    days after the date of receipt from the Secretary of the \n    information described in paragraph (1) for such year, shall \n    provide to the Secretary a rebate that is equal to the amount \n    specified in subsection (b) for such dosage form and strength \n    with respect to such drug for such year.\n``(b) Rebate Amount.--\n        ``(1) In general.--\n                ``(A) Calculation.--For purposes of this section, \n            the amount specified in this subsection for a dosage \n            form and strength with respect to a part D rebatable \n            drug and applicable year is, subject to subparagraph \n            (B) of this paragraph and subparagraphs (B) and (C) of \n            paragraph (5), the amount equal to the product of--\n                        ``(i) the total number of units that are \n                    used to calculate the average manufacturer \n                    price of such dosage form and strength with \n                    respect to such part D rebatable drug, as \n                    reported by the manufacturer of such drug under \n                    section 1927 for each recent rebate period \n                    under such section, with respect to such year, \n                    under such section for which such information \n                    is available; and\n                        ``(ii) the amount (if any) by which--\n                                ``(I) the annual manufacturer price \n                            (as determined in paragraph (2)) paid \n                            for such dosage form and strength with \n                            respect to such part D rebatable drug \n                            for the year; exceeds\n                                ``(II) the inflation-adjusted \n                            payment amount determined under \n                            paragraph (3) for such dosage form and \n                            strength with respect to such part D \n                            rebatable drug for the year.\n                ``(B) Excluded units.--For purposes of subparagraph \n            (A)(i), the Secretary shall exclude from the total \n            number of units for a dosage form and strength with \n            respect to a part D rebatable drug and the most recent \n            rebate period under section 1927, with respect to an \n            applicable year, for which such information is \n            available, units of each dosage form and strength of \n            such part D rebatable drug, for which payment was made \n            under a State plan under title XIX (or waiver of such \n            plan), as reported by States under section \n            1927(b)(2)(A) for such rebate period.\n        ``(2) Determination of annual manufacturer price.--The \n    annual manufacturer price determined under this paragraph for a \n    dosage form and strength, with respect to a part D rebatable \n    drug and an applicable year, is the sum of the products of--\n                ``(A) the average manufacturer price (as defined in \n            subsection (g)(6)) of such dosage form and strength, as \n            calculated for a unit of such drug, with respect to \n            each of the calendar quarters of such year; and\n                ``(B) the ratio of--\n                        ``(i) the total number of units of such \n                    dosage form and strength reported for the \n                    purpose of calculating average manufacturer \n                    price under section 1927 during each such \n                    calendar quarter of such year; to\n                        ``(ii) the total number of units of such \n                    dosage form and strength reported for the \n                    purpose of calculating average manufacturer \n                    price under section 1927 during such year, as \n                    determined by the Secretary.\n        ``(3) Determination of inflation-adjusted payment amount.--\n    The inflation-adjusted payment amount determined under this \n    paragraph for a dosage form and strength with respect to a part \n    D rebatable drug for an applicable year, subject to \n    subparagraphs (A) and (D) of paragraph (5), is--\n                ``(A) the benchmark year manufacturer price \n            determined under paragraph (4) for such dosage form and \n            strength with respect to such drug and year; increased \n            by\n                ``(B) the percentage by which the applicable year \n            CPI-U (as defined in subsection (g)(5)) for the year \n            exceeds the benchmark period CPI-U (as defined in \n            subsection (g)(4)).\n        ``(4) Determination of benchmark year manufacturer price.--\n    The benchmark year manufacturer price determined under this \n    paragraph for a dosage form and strength, with respect to a \n    part D rebatable drug and an applicable year, is the sum of the \n    products of--\n                ``(A) the average manufacturer price (as defined in \n            subsection (g)(6)) of such dosage form and strength, as \n            calculated for a unit of such drug, with respect to \n            each of the calendar quarters of the payment amount \n            benchmark year (as defined in subsection (g)(3)); and\n                ``(B) the ratio of--\n                        ``(i) the total number of units of such \n                    dosage form and strength dispensed during each \n                    such calendar quarter of such payment amount \n                    benchmark year; to\n                        ``(ii) the total number of units of such \n                    dosage form and strength dispensed during such \n                    payment amount benchmark year.\n        ``(5) Special treatment of certain drugs and exemption.--\n                ``(A) Subsequently approved drugs.--In the case of \n            a part D rebatable drug first approved or licensed by \n            the Food and Drug Administration after January 1, 2016, \n            subparagraphs (A) and (B) of paragraph (4) shall be \n            applied as if the term `payment amount benchmark year' \n            were defined under subsection (g)(3) as the first \n            calendar year beginning after the day on which the drug \n            was first marketed by any manufacturer and subparagraph \n            (B) of paragraph (3) shall be applied as if the term \n            `benchmark period CPI-U' were defined under subsection \n            (g)(4) as if the reference to `January 2016' under such \n            subsection were a reference to `January of the first \n            year beginning after the date on which the drug was \n            first marketed by any manufacturer'.\n                ``(B) Exemption for shortages.--The Secretary may \n            reduce or waive the rebate under paragraph (1) with \n            respect to a part D rebatable drug that is described as \n            currently in shortage on the shortage list in effect \n            under section 506E of the Federal Food, Drug, and \n            Cosmetic Act or in the case of other exigent \n            circumstances, as determined by the Secretary.\n                ``(C) Treatment of new formulations.--\n                        ``(i) In general.--In the case of a part D \n                    rebatable drug that is a line extension of a \n                    part D rebatable drug that is an oral solid \n                    dosage form, the Secretary shall establish a \n                    formula for determining the amount specified in \n                    this subsection with respect to such part D \n                    rebatable drug and an applicable year with \n                    consideration of the original part D rebatable \n                    drug.\n                        ``(ii) Line extension defined.--In this \n                    subparagraph, the term `line extension' means, \n                    with respect to a part D rebatable drug, a new \n                    formulation of the drug, such as an extended \n                    release formulation, but does not include an \n                    abuse-deterrent formulation of the drug (as \n                    determined by the Secretary), regardless of \n                    whether such abuse-deterrent formulation is an \n                    extended release formulation.\n                ``(D) Selected drugs.--In the case of a part D \n            rebatable drug that is a selected drug (as defined in \n            section 1192(c)) for a price applicability period (as \n            defined in section 1191(b)(2))--\n                        ``(i) for plan years during such period for \n                    which a maximum fair price (as defined in \n                    section 1191(c)(2)) for such drug has been \n                    determined and is applied under part E of title \n                    XI, the rebate under subsection (a)(1)(B) shall \n                    be waived; and\n                        ``(ii) in the case such drug is determined \n                    (pursuant to such section 1192(c)) to no longer \n                    be a selected drug, for each applicable year \n                    beginning after the price applicability period \n                    with respect to such drug, subparagraphs (A) \n                    and (B) of paragraph (4) shall be applied as if \n                    the term `payment amount benchmark year' were \n                    defined under subsection (g)(3) as the last \n                    year beginning during such price applicability \n                    period with respect to such selected drug and \n                    subparagraph (B) of paragraph (3) shall be \n                    applied as if the term `benchmark period CPI-U' \n                    were defined under subsection (g)(4) as if the \n                    reference to `January 2016' under such \n                    subsection were a reference to January of the \n                    last year beginning during such price \n                    applicability period with respect to such drug.\n``(c) Rebate Deposits.--Amounts paid as rebates under subsection \n")),(0,i.kt)("p",null,"(b) shall be deposited into the Medicare Prescription Drug Account in\nthe Federal Supplementary Medical Insurance Trust Fund established\nunder section 1841.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(d) Information.--For purposes of carrying out this section, the \nSecretary shall use information submitted by manufacturers under \nsection 1927(b)(3) and information submitted by States under section \n1927(b)(2)(A).\n    "),"(e) Civil Money Penalty.--If a manufacturer of a part D rebatable\ndrug has failed to comply with the requirement under subsection\n(a)(1)(B) with respect to such drug for an applicable year, the\nmanufacturer shall be subject to, in accordance with a process\nestablished by the Secretary pursuant to regulations, a civil money\npenalty in an amount equal to 125 percent of the amount specified in\nsubsection (b) for such drug for such year. The provisions of section\n1128A (other than subsections (a) (with respect to amounts of penalties\nor additional assessments) and (b)) shall apply to a civil money\npenalty under this subsection in the same manner as such provisions\napply to a penalty or proceeding under section 1128A(a).\n",(0,i.kt)("inlineCode",{parentName:"p"},"(f) Judicial Review.--There shall be no judicial review of the \nfollowing:\n            "),"(1) The determination of units under this section.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(2) The determination of whether a drug is a part D \n        rebatable drug under this section.\n            "),"(3) The calculation of the rebate amount under this\nsection.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(g) Definitions.--In this section:\n            "),"(1) Part d rebatable drug defined.--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(A) In general.--The term `part D rebatable drug' \n                means a drug or biological that would (without \n                application of this section) be a covered part D drug, \n                except such term shall, with respect to an applicable \n                year, not include such a drug or biological if the \n                average annual total cost under this part for such year \n                per individual who uses such a drug or biological, as \n                determined by the Secretary, is less than, subject to \n                subparagraph (B), $100, as determined by the Secretary \n                using the most recent data available or, if data is not \n                available, as estimated by the Secretary.\n                    "),"(B) Increase.--The dollar amount applied under\nsubparagraph (A)--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(i) for 2024, shall be the dollar amount \n                        specified under such subparagraph for 2023, \n                        increased by the percentage increase in the \n                        consumer price index for all urban consumers \n                        (United States city average) for the 12-month \n                        period beginning with January of 2023; and\n                            "),"(ii) for a subsequent year, shall be the\ndollar amount specified in this subparagraph\nfor the previous year, increased by the\npercentage increase in the consumer price index\nfor all urban consumers (United States city\naverage) for the 12-month period beginning with\nJanuary of the previous year.\nAny dollar amount specified under this subparagraph\nthat is not a multiple of $10 shall be rounded to the\nnearest multiple of $10.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(2) Unit defined.--The term `unit' means, with respect to \n        a part D rebatable drug, the lowest identifiable quantity (such \n        as a capsule or tablet, milligram of molecules, or grams) of \n        the part D rebatable drug, including data reported under \n        section 1927.\n            "),"(3) Payment amount benchmark year.--The term ",(0,i.kt)("inlineCode",{parentName:"p"},"payment \n        amount benchmark year' means the year beginning January 1, \n        2016.\n            ``(4) Benchmark period cpi-u.--The term "),"benchmark period\nCPI-U' means the consumer price index for all urban consumers\n(United States city average) for January 2016.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(5) Applicable year cpi-u.--The term `applicable year \n        CPI-U' means, with respect to an applicable year, the consumer \n        price index for all urban consumers (United States city \n        average) for January of such year.\n            "),"(6) Average manufacturer price.--The term ",(0,i.kt)("inlineCode",{parentName:"p"},"average \n        manufacturer price' has the meaning, with respect to a part D \n        rebatable drug of a manufacturer, given such term in section \n        1927(k)(1), with respect to a covered outpatient drug of a \n        manufacturer for a rebate period under section 1927.\n            ``(7) Applicable year.--The term "),"applicable year' means a\nyear beginning with 2023.''.\n(b) Conforming Amendments.--\n(1) To part b asp calculation.--Section 1847A(c)(3) of the\nSocial Security Act (42 U.S.C. 1395w-3a(c)(3)), as amended by\nsection 139101(c)(1), is further amended by striking ",(0,i.kt)("inlineCode",{parentName:"p"},"section \n        1927 or section 1834(z)'' and inserting "),"section 1927, section\n1834(z), or section 1860D-14B''.\n(2) Excluding part d drug inflation rebate from best\nprice.--Section 1927(c)(1)(C)(ii)(I) of the Social Security Act\n(42 U.S.C. 1396r-8(c)(1)(C)(ii)(I)), as amended by section\n139101(c)(2), is further amended by striking ",(0,i.kt)("inlineCode",{parentName:"p"},"or section \n        1834(z)'' and inserting "),", section 1834(z), or section 1860D-\n14B''.\n(3) Coordination with medicaid rebate information\ndisclosure.--Section 1927(b)(3)(D)(i) of the Social Security\nAct (42 U.S.C. 1396r-8(b)(3)(D)(i)), as amended by section\n139101(c)(3), is further amended by striking ",(0,i.kt)("inlineCode",{parentName:"p"},"or section \n        1834(z)'' and inserting "),", section 1834(z), or section 1860D-\n14B''."),(0,i.kt)("p",null,"PART 3--PART D IMPROVEMENTS AND MAXIMUM OUT-OF-POCKET CAP FOR MEDICARE\nBENEFICIARIES"),(0,i.kt)("p",null,"SEC. 139201. MEDICARE PART D BENEFIT REDESIGN."),(0,i.kt)("pre",null,(0,i.kt)("code",{parentName:"pre"},"(a) Benefit Structure Redesign.--Section 1860D-2(b) of the Social \n")),(0,i.kt)("p",null,"Security Act (42 U.S.C. 1395w-102(b)) is amended--\n(1) in paragraph (2)--\n(A) in subparagraph (A), in the matter preceding\nclause (i), by inserting ",(0,i.kt)("inlineCode",{parentName:"p"},"for a year preceding 2024 \n                and for costs above the annual deductible specified in \n                paragraph (1) and up to the annual out-of-pocket \n                threshold specified in paragraph (4)(B) for 2024 and \n                each subsequent year'' after "),"paragraph (3)'';\n(B) in subparagraph (C)--\n(i) in clause (i), in the matter preceding\nsubclause (I), by inserting ",(0,i.kt)("inlineCode",{parentName:"p"},"for a year \n                        preceding 2024,'' after "),"paragraph (4),''; and\n(ii) in clause (ii)(III), by striking ",(0,i.kt)("inlineCode",{parentName:"p"},"and \n                        each subsequent year'' and inserting "),"through\n2023''; and\n(C) in subparagraph (D)--\n(i) in clause (i)--\n(I) in the matter preceding\nsubclause (I), by inserting ",(0,i.kt)("inlineCode",{parentName:"p"},"for a \n                                year preceding 2024,'' after \n                                "),"paragraph (4),''; and\n(II) in subclause (I)(bb), by\nstriking ",(0,i.kt)("inlineCode",{parentName:"p"},"a year after 2018'' and \n                                inserting "),"each of years 2018 through\n2023''; and\n(ii) in clause (ii)(V), by striking ",(0,i.kt)("inlineCode",{parentName:"p"},"2019 \n                        and each subsequent year'' and inserting "),"each\nof years 2019 through 2023'';\n(2) in paragraph (3)(A)--\n(A) in the matter preceding clause (i), by\ninserting ",(0,i.kt)("inlineCode",{parentName:"p"},"for a year preceding 2024,'' after "),"and\n(4),''; and\n(B) in clause (ii), by striking ",(0,i.kt)("inlineCode",{parentName:"p"},"for a subsequent \n                year'' and inserting "),"for each of years 2007 through\n2023''; and\n(3) in paragraph (4)--\n(A) in subparagraph (A)--\n(i) in clause (i)--\n(I) by redesignating subclauses (I)\nand (II) as items (aa) and (bb),\nrespectively, and moving the margin of\neach such redesignated item 2 ems to\nthe right;\n(II) in the matter preceding item\n(aa), as redesignated by subclause (I),\nby striking ",(0,i.kt)("inlineCode",{parentName:"p"},"is equal to the greater \n                                of--'' and inserting "),"is equal to--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(I) for a year preceding 2024, \n                                the greater of--'';\n                                    (III) by striking the period at the \n                                end of item (bb), as redesignated by \n                                subclause (I), and inserting "),"; and'';\nand\n(IV) by adding at the end the\nfollowing:\n",(0,i.kt)("inlineCode",{parentName:"p"},"(II) for 2024 and each succeeding \n                                year, $0.''; and\n                            (ii) in clause (ii), by striking "),"clause\n(i)(I)'' and inserting ",(0,i.kt)("inlineCode",{parentName:"p"},"clause (i)(I)(aa)'';\n                    (B) in subparagraph (B)--\n                            (i) in clause (i)--\n                                    (I) in subclause (V), by striking \n                                "),"or'' at the end;\n(II) in subclause (VI)--\n(aa) by striking ",(0,i.kt)("inlineCode",{parentName:"p"},"for a \n                                        subsequent year'' and inserting \n                                        "),"for each of years 2021\nthrough 2023''; and\n(bb) by striking the period\nat the end and inserting a\nsemicolon; and\n(III) by adding at the end the\nfollowing new subclauses:\n",(0,i.kt)("inlineCode",{parentName:"p"},"(VII) for 2024, is equal to \n                                $2,000; or\n                                    "),"(VIII) for a subsequent year, is\nequal to the amount specified in this\nsubparagraph for the previous year,\nincreased by the annual percentage\nincrease described in paragraph (6) for\nthe year involved.''; and\n(ii) in clause (ii), by striking ",(0,i.kt)("inlineCode",{parentName:"p"},"clause \n                        (i)(II)'' and inserting "),"clause (i)'';\n(C) in subparagraph (C)(i), by striking ",(0,i.kt)("inlineCode",{parentName:"p"},"and for \n                amounts'' and inserting "),"and, for a year preceding\n2024, for amounts''; and\n(D) in subparagraph (E), by striking ",(0,i.kt)("inlineCode",{parentName:"p"},"In \n                applying'' and inserting "),"For each of years 2011\nthrough 2023, in applying''.\n(b) Decreasing Reinsurance Payment Amount.--Section 1860D-15(b)(1)\nof the Social Security Act (42 U.S.C. 1395w-115(b)(1)) is amended by\ninserting after ",(0,i.kt)("inlineCode",{parentName:"p"},"80 percent'' the following: "),"(or, with respect to a\ncoverage year after 2023, 20 percent)''.\n(c) Manufacturer Discount Program.--\n(1) In general.--Part D of title XVIII of the Social\nSecurity Act (42 U.S.C. 1395w-101 et seq.), as amended by\nsection 139102, is further amended by inserting after section\n1860D-14B the following new section:"),(0,i.kt)("p",null,"``SEC. 1860D-14C. MANUFACTURER DISCOUNT PROGRAM."),(0,i.kt)("pre",null,(0,i.kt)("code",{parentName:"pre"},"``(a) Establishment.--The Secretary shall establish a manufacturer \n")),(0,i.kt)("p",null,"discount program (in this section referred to as the ",(0,i.kt)("inlineCode",{parentName:"p"},"program'). Under \nthe program, the Secretary shall enter into agreements described in \nsubsection (b) with manufacturers and provide for the performance of \nthe duties described in subsection (c). The Secretary shall establish a \nmodel agreement for use under the program by not later than January 1, \n2023, in consultation with manufacturers, and allow for comment on such \nmodel agreement.\n    ``(b) Terms of Agreement.--\n            ``(1) In general.--\n                    ``(A) Agreement.--An agreement under this section \n                shall require the manufacturer to provide applicable \n                beneficiaries access to discounted prices for \n                applicable drugs of the manufacturer that are dispensed \n                on or after January 1, 2024.\n                    ``(B) Provision of discounted prices at the point-\n                of-sale.--The discounted prices described in \n                subparagraph (A) shall be provided to the applicable \n                beneficiary at the pharmacy or by the mail order \n                service at the point-of-sale of an applicable drug.\n                    ``(C) Timing of agreement.--\n                            ``(i) Special rule for 2024.--In order for \n                        an agreement with a manufacturer to be in \n                        effect under this section with respect to the \n                        period beginning on January 1, 2024, and ending \n                        on December 31, 2024, the manufacturer shall \n                        enter into such agreement not later than 30 \n                        days after the date of the establishment of a \n                        model agreement under subsection (a).\n                            ``(ii) 2025 and subsequent years.--In order \n                        for an agreement with a manufacturer to be in \n                        effect under this section with respect to plan \n                        year 2025 or a subsequent plan year, the \n                        manufacturer shall enter into such agreement \n                        (or such agreement shall be renewed under \n                        paragraph (4)(A)) not later than January 30 of \n                        the preceding year.\n            ``(2) Provision of appropriate data.--Each manufacturer \n        with an agreement in effect under this section shall collect \n        and have available appropriate data, as determined by the \n        Secretary, to ensure that it can demonstrate to the Secretary \n        compliance with the requirements under the program.\n            ``(3) Compliance with requirements for administration of \n        program.--Each manufacturer with an agreement in effect under \n        this section shall comply with requirements imposed by the \n        Secretary or a third party with a contract under subsection \n        (d)(3), as applicable, for purposes of administering the \n        program, including any determination under subparagraph (A) of \n        subsection (c)(1) or procedures established under such \n        subsection (c)(1).\n            ``(4) Length of agreement.--\n                    ``(A) In general.--An agreement under this section \n                shall be effective for an initial period of not less \n                than 12 months and shall be automatically renewed for a \n                period of not less than 1 year unless terminated under \n                subparagraph (B).\n                    ``(B) Termination.--\n                            ``(i) By the secretary.--The Secretary may \n                        provide for termination of an agreement under \n                        this section for a knowing and willful \n                        violation of the requirements of the agreement \n                        or other good cause shown. Such termination \n                        shall not be effective earlier than 30 days \n                        after the date of notice to the manufacturer of \n                        such termination. The Secretary shall provide, \n                        upon request, a manufacturer with a hearing \n                        concerning such a termination, and such hearing \n                        shall take place prior to the effective date of \n                        the termination with sufficient time for such \n                        effective date to be repealed if the Secretary \n                        determines appropriate.\n                            ``(ii) By a manufacturer.--A manufacturer \n                        may terminate an agreement under this section \n                        for any reason. Any such termination shall be \n                        effective, with respect to a plan year--\n                                    ``(I) if the termination occurs \n                                before January 30 of a plan year, as of \n                                the day after the end of the plan year; \n                                and\n                                    ``(II) if the termination occurs on \n                                or after January 30 of a plan year, as \n                                of the day after the end of the \n                                succeeding plan year.\n                            ``(iii) Effectiveness of termination.--Any \n                        termination under this subparagraph shall not \n                        affect discounts for applicable drugs of the \n                        manufacturer that are due under the agreement \n                        before the effective date of its termination.\n                            ``(iv) Notice to third party.--The \n                        Secretary shall provide notice of such \n                        termination to a third party with a contract \n                        under subsection (d)(3) within not less than 30 \n                        days before the effective date of such \n                        termination.\n    ``(c) Duties Described.--The duties described in this subsection \nare the following:\n            ``(1) Administration of program.--Administering the \n        program, including--\n                    ``(A) the determination of the amount of the \n                discounted price of an applicable drug of a \n                manufacturer;\n                    ``(B) the establishment of procedures under which \n                discounted prices are provided to applicable \n                beneficiaries at pharmacies or by mail order service at \n                the point-of-sale of an applicable drug;\n                    ``(C) the establishment of procedures to ensure \n                that, not later than the applicable number of calendar \n                days after the dispensing of an applicable drug by a \n                pharmacy or mail order service, the pharmacy or mail \n                order service is reimbursed for an amount equal to the \n                difference between--\n                            ``(i) the negotiated price of the \n                        applicable drug; and\n                            ``(ii) the discounted price of the \n                        applicable drug;\n                    ``(D) the establishment of procedures to ensure \n                that the discounted price for an applicable drug under \n                this section is applied before any coverage or \n                financial assistance under other health benefit plans \n                or programs that provide coverage or financial \n                assistance for the purchase or provision of \n                prescription drug coverage on behalf of applicable \n                beneficiaries as the Secretary may specify; and\n                    ``(E) providing a reasonable dispute resolution \n                mechanism to resolve disagreements between \n                manufacturers, applicable beneficiaries, and the third \n                party with a contract under subsection (d)(3).\n            ``(2) Monitoring compliance.--\n                    ``(A) In general.--The Secretary shall monitor \n                compliance by a manufacturer with the terms of an \n                agreement under this section.\n                    ``(B) Notification.--If a third party with a \n                contract under subsection (d)(3) determines that the \n                manufacturer is not in compliance with such agreement, \n                the third party shall notify the Secretary of such \n                noncompliance for appropriate enforcement under \n                subsection (e).\n            ``(3) Collection of data from prescription drug plans and \n        ma-pd plans.--The Secretary may collect appropriate data from \n        prescription drug plans and MA-PD plans in a timeframe that \n        allows for discounted prices to be provided for applicable \n        drugs under this section.\n    ``(d) Administration.--\n            ``(1) In general.--Subject to paragraph (2), the Secretary \n        shall provide for the implementation of this section, including \n        the performance of the duties described in subsection (c).\n            ``(2) Limitation.--In providing for the implementation of \n        this section, the Secretary shall not receive or distribute any \n        funds of a manufacturer under the program.\n            ``(3) Contract with third parties.--The Secretary shall \n        enter into a contract with 1 or more third parties to \n        administer the requirements established by the Secretary in \n        order to carry out this section. At a minimum, the contract \n        with a third party under the preceding sentence shall require \n        that the third party--\n                    ``(A) receive and transmit information between the \n                Secretary, manufacturers, and other individuals or \n                entities the Secretary determines appropriate;\n                    ``(B) receive, distribute, or facilitate the \n                distribution of funds of manufacturers to appropriate \n                individuals or entities in order to meet the \n                obligations of manufacturers under agreements under \n                this section;\n                    ``(C) provide adequate and timely information to \n                manufacturers, consistent with the agreement with the \n                manufacturer under this section, as necessary for the \n                manufacturer to fulfill its obligations under this \n                section; and\n                    ``(D) permit manufacturers to conduct periodic \n                audits, directly or through contracts, of the data and \n                information used by the third party to determine \n                discounts for applicable drugs of the manufacturer \n                under the program.\n            ``(4) Performance requirements.--The Secretary shall \n        establish performance requirements for a third party with a \n        contract under paragraph (3) and safeguards to protect the \n        independence and integrity of the activities carried out by the \n        third party under the program under this section.\n            ``(5) Implementation.--The Secretary may implement the \n        program under this section by program instruction or otherwise.\n            ``(6) Administration.--Chapter 35 of title 44, United \n        States Code, shall not apply to the program under this section.\n    ``(e) Enforcement.--\n            ``(1) Audits.--Each manufacturer with an agreement in \n        effect under this section shall be subject to periodic audit by \n        the Secretary.\n            ``(2) Civil money penalty.--\n                    ``(A) In general.--The Secretary may impose a civil \n                money penalty on a manufacturer that fails to provide \n                applicable beneficiaries discounts for applicable drugs \n                of the manufacturer in accordance with such agreement \n                for each such failure in an amount the Secretary \n                determines is equal to the sum of--\n                            ``(i) the amount that the manufacturer \n                        would have paid with respect to such discounts \n                        under the agreement, which will then be used to \n                        pay the discounts which the manufacturer had \n                        failed to provide; and\n                            ``(ii) 25 percent of such amount.\n                    ``(B) Application.--The provisions of section 1128A \n                (other than subsections (a) and (b)) shall apply to a \n                civil money penalty under this paragraph in the same \n                manner as such provisions apply to a penalty or \n                proceeding under section 1128A(a).\n    ``(f) Clarification Regarding Availability of Other Covered Part D \nDrugs.--Nothing in this section shall prevent an applicable beneficiary \nfrom purchasing a covered part D drug that is not an applicable drug \n(including a generic drug or a drug that is not on the formulary of the \nprescription drug plan or MA-PD plan that the applicable beneficiary is \nenrolled in).\n    ``(g) Definitions.--In this section:\n            ``(1) Applicable beneficiary.--The term "),"applicable\nbeneficiary' means an individual who, on the date of dispensing\na covered part D drug--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(A) is enrolled in a prescription drug plan or an \n                MA-PD plan;\n                    "),"(B) is not enrolled in a qualified retiree\nprescription drug plan; and\n",(0,i.kt)("inlineCode",{parentName:"p"},"(C) has incurred costs, as determined in \n                accordance with section 1860D-2(b)(4)(C), for covered \n                part D drugs in the year that exceed the annual \n                deductible with respect to such individual for such \n                year, as specified in section 1860D-2(b)(1), section \n                1860D-14(a)(1)(B), or section 1860D-14(a)(2)(B), as \n                applicable.\n            "),"(2) Applicable drug.--The term ",(0,i.kt)("inlineCode",{parentName:"p"},"applicable drug', with \n        respect to an applicable beneficiary--\n                    ``(A) means a covered part D drug--\n                            ``(i) approved under a new drug application \n                        under section 505(c) of the Federal Food, Drug, \n                        and Cosmetic Act or, in the case of a biologic \n                        product, licensed under section 351 of the \n                        Public Health Service Act; and\n                            ``(ii)(I) if the PDP sponsor of the \n                        prescription drug plan or the MA organization \n                        offering the MA-PD plan uses a formulary, which \n                        is on the formulary of the prescription drug \n                        plan or MA-PD plan that the applicable \n                        beneficiary is enrolled in;\n                            ``(II) if the PDP sponsor of the \n                        prescription drug plan or the MA organization \n                        offering the MA-PD plan does not use a \n                        formulary, for which benefits are available \n                        under the prescription drug plan or MA-PD plan \n                        that the applicable beneficiary is enrolled in; \n                        or\n                            ``(III) is provided through an exception or \n                        appeal; and\n                    ``(B) does not include a selected drug (as defined \n                in section 1192(c)) during a price applicability period \n                (as defined in section 1191(b)(2)) with respect to such \n                drug.\n            ``(3) Applicable number of calendar days.--The term \n        "),"applicable number of calendar days' means--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(A) with respect to claims for reimbursement \n                submitted electronically, 14 days; and\n                    "),"(B) with respect to claims for reimbursement\nsubmitted otherwise, 30 days.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(4) Discounted price.--\n                    "),"(A) In general.--The term ",(0,i.kt)("inlineCode",{parentName:"p"},"discounted price' \n                means, with respect to an applicable drug of a \n                manufacturer dispensed during a year to an applicable \n                beneficiary--\n                            ``(i) who has not incurred costs, as \n                        determined in accordance with section 1860D-\n                        2(b)(4)(C), for covered part D drugs in the \n                        year that are equal to or exceed the annual \n                        out-of-pocket threshold specified in section \n                        1860D-2(b)(4)(B)(i) for the year, 90 percent of \n                        the negotiated price of such drug; and\n                            ``(ii) who has incurred such costs, as so \n                        determined, in the year that are equal to or \n                        exceed such threshold for the year, 70 percent \n                        of the negotiated price of such drug.\n                    ``(B) Clarification.--Nothing in this section shall \n                be construed as affecting the responsibility of an \n                applicable beneficiary for payment of a dispensing fee \n                for an applicable drug.\n                    ``(C) Special case for certain claims.--\n                            ``(i) Claims spanning deductible.--In the \n                        case where the entire amount of the negotiated \n                        price of an individual claim for an applicable \n                        drug with respect to an applicable beneficiary \n                        does not fall above the annual deductible \n                        specified in section 1860D-2(b)(1) for the \n                        year, the manufacturer of the applicable drug \n                        shall provide the discounted price under this \n                        section on only the portion of the negotiated \n                        price of the applicable drug that falls above \n                        such annual deductible.\n                            ``(ii) Claims spanning out-of-pocket \n                        threshold.--In the case where the entire amount \n                        of the negotiated price of an individual claim \n                        for an applicable drug with respect to an \n                        applicable beneficiary does not fall entirely \n                        below or entirely above the annual out-of-\n                        pocket threshold specified in section 1860D-\n                        2(b)(4)(B)(i) for the year, the manufacturer of \n                        the applicable drug shall provide the \n                        discounted price--\n                                    ``(I) in accordance with \n                                subparagraph (A)(i) on the portion of \n                                the negotiated price of the applicable \n                                drug that falls below such threshold; \n                                and\n                                    ``(II) in accordance with \n                                subparagraph (A)(ii) on the portion of \n                                such price of such drug that falls at \n                                or above such threshold.\n            ``(5) Manufacturer.--The term "),"manufacturer' means any\nentity which is engaged in the production, preparation,\npropagation, compounding, conversion, or processing of\nprescription drug products, either directly or indirectly by\nextraction from substances of natural origin, or independently\nby means of chemical synthesis, or by a combination of\nextraction and chemical synthesis. Such term does not include a\nwholesale distributor of drugs or a retail pharmacy licensed\nunder State law.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(6) Negotiated price.--The term `negotiated price' has \n        the meaning given such term in section 423.100 of title 42, \n        Code of Federal Regulations (or any successor regulation), \n        except that, with respect to an applicable drug, such \n        negotiated price shall not include any dispensing fee for the \n        applicable drug.\n            "),"(7) Qualified retiree prescription drug plan.--The term\n`qualified retiree prescription drug plan' has the meaning\ngiven such term in section 1860D-22(a)(2).''.\n(2) Sunset of medicare coverage gap discount program.--\nSection 1860D-14A of the Social Security Act (42 U.S.C. 1395-\n114a) is amended--\n(A) in subsection (a), in the first sentence, by\nstriking ",(0,i.kt)("inlineCode",{parentName:"p"},"The Secretary'' and inserting "),"Subject to\nsubsection (h), the Secretary''; and\n(B) by adding at the end the following new\nsubsection:\n",(0,i.kt)("inlineCode",{parentName:"p"},"(h) Sunset of Program.--\n            "),"(1) In general.--The program shall not apply with respect\nto applicable drugs dispensed on or after January 1, 2024, and,\nsubject to paragraph (2), agreements under this section shall\nbe terminated as of such date.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(2) Continued application for applicable drugs dispensed \n        prior to sunset.--The provisions of this section (including all \n        responsibilities and duties) shall continue to apply after \n        January 1, 2024, with respect to applicable drugs dispensed \n        prior to such date.''.\n            (3) Inclusion of actuarial value of manufacturer discounts \n        in bids.--Section 1860D-11 of the Social Security Act (42 \n        U.S.C. 1395w-111) is amended--\n                    (A) in subsection (b)(2)(C)(iii)--\n                            (i) by striking "),"assumptions regarding the\nreinsurance'' and inserting ",(0,i.kt)("inlineCode",{parentName:"p"},"assumptions \n                        regarding--\n                                    "),"(I) the reinsurance''; and\n(ii) by adding at the end the following:\n",(0,i.kt)("inlineCode",{parentName:"p"},"(II) for 2024 and each subsequent \n                                year, the manufacturer discounts \n                                provided under section 1860D-14C \n                                subtracted from the actuarial value to \n                                produce such bid; and''; and\n                    (B) in subsection (c)(1)(C)--\n                            (i) by striking "),"an actuarial valuation of\nthe reinsurance'' and inserting ",(0,i.kt)("inlineCode",{parentName:"p"},"an actuarial \n                        valuation of--\n                            "),"(i) the reinsurance'';\n(ii) in clause (i), as inserted by clause\n(i) of this subparagraph, by adding ",(0,i.kt)("inlineCode",{parentName:"p"},"and'' at \n                        the end; and\n                            (iii) by adding at the end the following:\n                            "),"(ii) for 2024 and each subsequent year,\nthe manufacturer discounts provided under\nsection 1860D-14C;''.\n(d) Conforming Amendments.--\n(1) Section 1860D-2 of the Social Security Act (42 U.S.C.\n1395w-102) is amended--\n(A) in subsection (a)(2)(A)(i)(I), by striking ",(0,i.kt)("inlineCode",{parentName:"p"},", \n                or an increase in the initial'' and inserting "),"or, for\na year preceding 2024, an increase in the initial'';\n(B) in subsection (c)(1)(C)--\n(i) in the subparagraph heading, by\nstriking ",(0,i.kt)("inlineCode",{parentName:"p"},"at initial coverage limit''; and\n                            (ii) by inserting "),"for a year preceding\n2024 or the annual out-of-pocket threshold\nspecified in subsection (b)(4)(B) for the year\nfor 2024 and each subsequent year'' after\n",(0,i.kt)("inlineCode",{parentName:"p"},"subsection (b)(3) for the year'' each place \n                        it appears; and\n                    (C) in subsection (d)(1)(A), by striking "),"or an\ninitial'' and inserting ",(0,i.kt)("inlineCode",{parentName:"p"},"or, for a year preceding \n                2024, an initial''.\n            (2) Section 1860D-4(a)(4)(B)(i) of the Social Security Act \n        (42 U.S.C. 1395w-104(a)(4)(B)(i)) is amended by striking "),"the\ninitial'' and inserting ",(0,i.kt)("inlineCode",{parentName:"p"},"for a year preceding 2024, the \n        initial''.\n            (3) Section 1860D-14(a) of the Social Security Act (42 \n        U.S.C. 1395w-114(a)) is amended--\n                    (A) in paragraph (1)--\n                            (i) in subparagraph (C), by striking "),"The\ncontinuation'' and inserting ",(0,i.kt)("inlineCode",{parentName:"p"},"For a year \n                        preceding 2024, the continuation'';\n                            (ii) in subparagraph (D)(iii), by striking \n                        "),"1860D-2(b)(4)(A)(i)(I)'' and inserting\n",(0,i.kt)("inlineCode",{parentName:"p"},"1860D-2(b)(4)(A)(i)(I)(aa)''; and\n                            (iii) in subparagraph (E), by striking \n                        "),"The elimination'' and inserting ",(0,i.kt)("inlineCode",{parentName:"p"},"For a year \n                        preceding 2024, the elimination''; and\n                    (B) in paragraph (2)--\n                            (i) in subparagraph (C), by striking "),"The\ncontinuation'' and inserting ",(0,i.kt)("inlineCode",{parentName:"p"},"For a year \n                        preceding 2024, the continuation''; and\n                            (ii) in subparagraph (E), by striking \n                        "),"1860D-2(b)(4)(A)(i)(I)'' and inserting\n",(0,i.kt)("inlineCode",{parentName:"p"},"1860D-2(b)(4)(A)(i)(I)(aa)''.\n            (4) Section 1860D-21(d)(7) of the Social Security Act (42 \n        U.S.C. 1395w-131(d)(7)) is amended by striking "),"section 1860D-\n2(b)(4)(B)(i)'' and inserting ",(0,i.kt)("inlineCode",{parentName:"p"},"section 1860D-2(b)(4)(C)(i)''.\n            (5) Section 1860D-22(a)(2)(A) of the Social Security Act \n        (42 U.S.C. 1395w-132(a)(2)(A)) is amended--\n                    (A) by striking "),"the value of any discount'' and\ninserting the following: ",(0,i.kt)("inlineCode",{parentName:"p"},"the value of--\n                            "),"(i) for years prior to 2024, any\ndiscount'';\n(B) in clause (i), as inserted by subparagraph (A)\nof this paragraph, by striking the period at the end\nand inserting ",(0,i.kt)("inlineCode",{parentName:"p"},"; and''; and\n                    (C) by adding at the end the following new clause:\n                            "),"(ii) for 2024 and each subsequent year,\nany discount provided pursuant to section\n1860D-14C.''.\n(6) Section 1860D-41(a)(6) of the Social Security Act (42\nU.S.C. 1395w-151(a)(6)) is amended--\n(A) by inserting ",(0,i.kt)("inlineCode",{parentName:"p"},"for a year before 2024'' after \n                "),"1860D-2(b)(3)''; and\n(B) by inserting ",(0,i.kt)("inlineCode",{parentName:"p"},"for such year'' before the \n                period.\n            (7) Section 1860D-43 of the Social Security Act (42 U.S.C. \n        1395w-153) is amended--\n                    (A) in subsection (a)--\n                            (i) by striking paragraph (1) and inserting \n                        the following:\n            "),"(1) participate in--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(A) for 2011 through 2023, the Medicare coverage \n                gap discount program under section 1860D-14A; and\n                    "),"(B) for 2024 and each subsequent year, the\nmanufacturer discount program under section 1860D-\n14C;'';\n(ii) by striking paragraph (2) and\ninserting the following:\n",(0,i.kt)("inlineCode",{parentName:"p"},"(2) have entered into and have in effect--\n                    "),"(A) for 2011 through 2023, an agreement described\nin subsection (b) of section 1860D-14A with the\nSecretary; and\n",(0,i.kt)("inlineCode",{parentName:"p"},"(B) for 2024 and each subsequent year, an \n                agreement described in subsection (b) of section 1860D-\n                14C with the Secretary; and''; and\n                            (iii) by striking paragraph (3) and \n                        inserting the following:\n            "),"(3) have entered into and have in effect, under terms and\nconditions specified by the Secretary--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(A) for 2011 through 2023, a contract with a \n                third party that the Secretary has entered into a \n                contract with under subsection (d)(3) of section 1860D-\n                14A; and\n                    "),"(B) for 2024 and each subsequent year, a contract\nwith a third party that the Secretary has entered into\na contract with under subsection (d)(3) of section\n1860D-14C.''; and\n(B) by striking subsection (b) and inserting the\nfollowing:\n",(0,i.kt)("inlineCode",{parentName:"p"},"(b) Effective Date.--Paragraphs (1)(A), (2)(A), and (3)(A) of \nsubsection (a) shall apply to covered part D drugs dispensed under this \npart on or after January 1, 2011, and before January 1, 2024, and \nparagraphs (1)(B), (2)(B), and (3)(B) of such subsection shall apply to \ncovered part D drugs dispensed under this part on or after January 1, \n2024.''.\n            (8) Section 1927 of the Social Security Act (42 U.S.C. \n        1396r-8) is amended--\n                    (A) in subsection (c)(1)(C)(i)(VI), by inserting \n                before the period at the end the following: "),"or under\nthe manufacturer discount program under section 1860D-\n14C''; and\n(B) in subsection (k)(1)(B)(i)(V), by inserting\nbefore the period at the end the following: ``or under\nsection 1860D-14C''.\n(e) Effective Date.--The amendments made by this section shall\napply with respect to plan year 2024 and subsequent plan years."),(0,i.kt)("p",null,"SEC. 139202. ALLOWING CERTAIN ENROLLEES OF PRESCRIPTION DRUG PLANS AND\nMA-PD PLANS UNDER MEDICARE PROGRAM TO SPREAD OUT COST-\nSHARING UNDER CERTAIN CIRCUMSTANCES."),(0,i.kt)("pre",null,(0,i.kt)("code",{parentName:"pre"},"Section 1860D-2(b)(2) of the Social Security Act (42 U.S.C. 1395w-\n")),(0,i.kt)("p",null,"102(b)(2)), as amended by section 139201, is further amended--\n(1) in subparagraph (A), by striking ",(0,i.kt)("inlineCode",{parentName:"p"},"Subject to \n        subparagraphs (C) and (D)'' and inserting "),"Subject to\nsubparagraphs (C), (D), and (E)''; and\n(2) by adding at the end the following new subparagraph:\n``(E) Enrollee option regarding spreading cost-\nsharing.--The Secretary shall establish by regulation a\nprocess under which, with respect to plan year 2024 and\nsubsequent plan years, a prescription drug plan or an\nMA-PD plan shall, in the case of a part D eligible\nindividual enrolled with such plan for such plan year\nwho is not a subsidy eligible individual (as defined in\nsection 1860D-14(a)(3)) and with respect to whom the\nplan projects that the dispensing of the first fill of\na covered part D drug to such individual will result in\nthe individual incurring costs that are equal to or\nabove the annual out-of-pocket threshold specified in\nparagraph (4)(B) for such plan year, provide such\nindividual with the option to make the coinsurance\npayment required under subparagraph (A) (for the\nportion of such costs that are not above such annual\nout-of-pocket threshold) in the form of periodic\ninstallments over the remainder of such plan year.''."),(0,i.kt)("pre",null,(0,i.kt)("code",{parentName:"pre"},"    PART 4--REPEAL OF CERTAIN PRESCRIPTION DRUG REBATE RULE\n")),(0,i.kt)("p",null,"SEC. 139301. PROHIBITING IMPLEMENTATION OF RULE RELATING TO ELIMINATING\nTHE ANTI-KICKBACK STATUTE SAFE HARBOR PROTECTION FOR\nPRESCRIPTION DRUG REBATES."),(0,i.kt)("pre",null,(0,i.kt)("code",{parentName:"pre"},"Beginning January 1, 2026, the Secretary of Health and Human \n")),(0,i.kt)("p",null,"Services shall not implement, administer, or enforce the provisions of\nthe final rule published by the Office of the Inspector General of the\nDepartment of Health and Human Services on November 30, 2020, and\ntitled ``Fraud and Abuse; Removal of Safe Harbor Protection for Rebates\nInvolving Prescription Pharmaceuticals and Creation of New Safe Harbor\nProtection for Certain Point-of-Sale Reductions in Price on\nPrescription Pharmaceuticals and Certain Pharmacy Benefit Manager\nService Fees'' (85 Fed. Reg. 76666).\nUnion Calendar No. 94"),(0,i.kt)("p",null,"117th CONGRESS"),(0,i.kt)("p",null,"  1st Session"),(0,i.kt)("pre",null,(0,i.kt)("code",{parentName:"pre"},"                           H. R. 5376\n\n                      [Report No. 117-130]\n")))}p.isMDXComponent=!0}}]);